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ABSTRACT 
 
 
This investigation attempts to examine the influences of validation on pharmaceutical 
processes especially at a new manufacturing facility that has to meet international 
requirements, and fulfil a cost effective business strategy.  At Aspen Pharmacare, a 
pharmaceutical organisation, there are two manufacturing facilities situated adjacent to 
each other, one new and one old. The new facility creates ideal opportunities to supply 
products to local and international markets.  
 
The investigation compares legal requirements from local and international regulatory 
authorities.  Validation and qualification practices as well as the problems encountered 
during the different phases are discussed. Particular attention is given to the validation 
approach at the new Aspen facility.  Problems and proposed solutions relating to the 
design review, installation, operational, and performance qualification are discussed.   
 
Validation of analytical methods for cleaning analysis, cleaning validation of 
equipment, and optimisation of some tablet manufacturing processes are described. 
Statistical evaluations of analytical results are included to find the optimum conditions 
for integrating new personnel with new processes and equipment.  A business model 
reviews the cost of non-conformances of the enalapril maleate 10 mg tablets 
manufactured at the two manufacturing facilities.  Finally the dissertation proves that 
validation is not only a regulatory requirement but that it also provides benefits such as 
adding value to the business, and ultimately reducing the cost of medicines. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 Plan of the Study 
 
The pharmaceutical industry is highly regulated with regards to practices and 
requirements that must be enforced while producing medicinal products for human and 
animal consumption.  These requirements differ from country to country with different 
countries subscribing to different Regulatory Authorities (e.g.  Medicine Control Council 
of South Africa, United States Food and Drug Administration, United Kingdom 
Medicine and Healthcare Product Regulatory Agency, etc.).  Each regulatory authority 
will have their list of requirements and regulations. Generally these requirements are 
very similar, but with some subtle differences. The important factor is how the different 
regulatory authorities enforce their requirements, which affects the manufacturing cost 
of pharmaceutical products and ultimately the price the consumer must pay for the 
products.   
 
In order to compete internationally, product quality and efficacy must be of a very high 
standard while the price is competitive.  Product quality standards are enforced by the 
various regulatory authorities.  However, price of goods and the associated costs must 
be balanced with the cost of quality and regulatory standards.  To achieve this delicate 
balance, products must be manufactured consistently with minimal rejects, re-
manipulations or accident for the market place.  Validation is a process that allows 
organisations to achieve this balance. 
 
The main objective of this project is to evaluate how Validation impacts on the 
principles of good manufacturing practices (GMP) of pharmaceutical products, in 
particular oral solid dosage medicines.  The focus will be to determine the advantages 
of implementing a structured validation programme in a pharmaceutical manufacturing 
facility. Aspects relating to qualification of pharmaceutical facilities and equipment, 
cleaning validation of equipment, factors associated with optimising some aspects of 
the tablet-making manufacturing processes, and process validation will be discussed.  
In addition the problems experienced in current practices as well as proposed solutions 
for such problems will be discussed for various phases of transforming a recently built 
pharmaceutical facility into a full scale, international production facility.  
     - 2 - 
A business model will be discussed at the end of the project.  The model will attempt to 
consider the costs associated with the manufacture of rejected products or non-
conforming products.  This will be done in the form of a comparative study looking at 
differences in the cost of non-conformance.  The study will compare the cost of 
Enalapril maleate 10 mg tablets manufactured in an older pharmaceutical facility 
(General Facility) versus the manufacture of Enalapril maleate 10 mg tablets in a new 
facility (Aspen OSD). Validation programmes are in place in both manufacturing 
facilities.  However, the Aspen OSD facility has an improved structured validation 
programme when compared to the General Facility.    
 
The expected outcome of the project is to prove that Validation in the pharmaceutical 
industry adds value by improving the quality of medicines, reducing rejects in 
manufacture and ultimately lowers the manufacturing cost of medicines. 
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1.2 Legal Requirements 
 
It is mandatory for pharmaceutical companies operating as a business to comply with 
the Integrated Medicines and Related Substances Control Act 101 of 1965 as 
amended [1].  Some of the objectives of Act 101 of 1965 as amended are:   
• “To provide for the registration of medicines and related substances intended for 
human and for animal use;  
• To provide for the establishment of a Medicines Control Council;  
• To provide for the control of medicines and scheduled substances and medical 
devices;  
• To make further provision for the prohibition on the sale of medicines which are 
subject to registration and which are not registered;  
• To provide for procedures that will expedite the registration of essential 
medicines, and for the re-evaluation of all medicines after five years;  
• To provide for measures for the supply of more affordable medicines in certain 
circumstances.” 
In the Republic of South Africa, the regulatory authority is the Medicines Control 
Council of South Africa.  The Medicines Control Council applies standards stipulated in 
the Medicines and Related Substances Control Act which governs the manufacture, 
distribution, sale, and marketing of medicines.  Pharmaceutical businesses are 
regulated to operate within the act. Guidelines are clearly outlined in a document 
“Guide to Manufacturing Practice for Medicine in South Africa” written by the 
Department of Health.  The “Guide to Manufacturing Practice for Medicine in South 
Africa” has been reformatted recently to remove barriers to trade in medicinal products, 
to promote uniformity in licensing decisions, and to ensure that high standards of 
quality assurance are maintained in the development, manufacture and control of 
medicinal products [2]. 
 
Pharmaceutical companies must comply with the guidelines to be able to manufacture 
pharmaceutical products intended for human and veterinary use.  Compliance to these 
guidelines is tested during inspection by members of the Inspectorate of the Medicines 
Control Council of South Africa.  This offers protection to patients and consumers of 
the pharmaceutical products as errors in the manufacture of medicinal products, 
advertently or inadvertently, may bear severe consequences, and may lead to fatalities 
of patients and consumers.   
     - 4 - 
1.3 Organisation background 
 
Aspen Pharmacare is Africa's largest pharmaceutical manufacturer and a major 
supplier of branded pharmaceutical and healthcare products to the Southern African 
and selected international markets.  Aspen Pharmacare is also Africa's largest 
manufacturer of generic pharmaceutical products and the leading supplier of generic 
medicines to both the private and public sectors in South Africa.  Aspen Pharmacare is 
based in South Africa with one of the manufacturing factories located in Korsten, Port 
Elizabeth called, Aspen Pharmacare Port Elizabeth.  Aspen Pharmacare Port 
Elizabeth manufacture, package, and distribute liquids, oral solid dosages, and semi 
solid dosages [3]. 
   
During January 2003, Aspen Pharmacare embarked on a major project of building a 
new pharmaceutical production facility adjacent to the existing premises for the 
purposes of manufacturing oral solid dosage (OSD) forms of medicines.  The new 
facility will be referred to as Aspen OSD from this point forward.  The first trial batch of 
tablets was manufactured in Aspen OSD in April 2004.  A series of subsequent trial 
batches followed to move the facility from the project phase to full scale production.   
 
In August 2004 the Aspen OSD facility was inspected by the Medicines Control 
Council.  The facility was approved for manufacturing of pharmaceutical products.  
Inspections followed from other international pharmaceutical regulatory authorities to 
approve the facility for the manufacture, packaging, distribution, and sale of products 
destined for international markets.  The international regulatory authorities included the 
World Health Organisation (WHO), the United Kingdom Medicine and Healthcare 
Product Regulatory Agency (MHRA), and the United States Food and Drug 
Administration (FDA).  In December 2004, Aspen OSD was granted permission to 
manufacture, package, distribute, and sell generic anti-retroviral treatment products to 
African countries from the United States Food and Drug Administration.  This is a very 
prestigious achievement that has been awarded to very few South African 
pharmaceutical manufacturers.  Seven months later Aspen OSD received approval 
from the United Kingdom Medicine and Healthcare Product Regulatory Agency, and 
the World Health Organisation to manufacture, package, and distribute products to the 
United Kingdom and to a group of African countries.   
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1.4 What is meant by “Validation?” 
 
The Registrar of Medicine [4] defines the term “Process Validation” as “documented 
evidence that the process, operated within established parameters, can perform 
effectively and reproducibly to produce medicinal products meeting predetermined 
specifications and quality attributes”  The United States Food and Drug Administration 
[5] defines the term Process Validation as follows; “Process Validation is establishing 
documented evidence which provide a high degree of assurance that specific 
processes will consistently produce products meeting predetermined specifications 
and quality characteristics”.  These definitions are very similar in meaning yet 
interpretation of each can be misunderstood.  In a nutshell validation is checking that 
equipment, systems, and processes work as intended by itself or integrated with other 
equipment or system, and by keeping these equipment, systems, and processes in a 
validated state, the products manufactured will be the same every time and will always 
meet specifications.  
 
In order to understand how validation is integrated into the pharmaceutical industry, 
one has to understand the principles of good manufacturing practices (GMP).  There 
are many different sections of GMP.  The Registrar of Medicine [6], lists various 
sections of GMP for pharmaceutical manufacture.  These include: 
1. Chapter 1 – Quality Management 
2. Chapter 2 – Personnel 
3. Chapter 3 – Premises and Equipment 
4. Chapter 4 – Documentation 
5. Chapter 5 – Production 
6. Chapter 6 – Quality Control  
7. Chapter 7 – Contract manufacture and analysis 
8. Chapter 8 – Complaints and product recall 
9. Chapter 9 – Self Inspection 
 Annexure 1 – Manufacture of sterile medicinal products 
 Annexure 2 – Manufacture of biological medicinal products for human use 
 Annexure 3 – Manufacture of radio pharmaceuticals 
 Annexure 4 – Manufacture of veterinary medicinal products other than 
immunologicals 
 Annexure 5 – Manufacture of immunological veterinary medical products 
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 Annexure 6 – Manufacture of medicinal gases 
 Annexure 7 – Manufacture of herbal medicinal products 
 Annexure 8 – Sampling of starting and packaging materials 
 Annexure 9 – Manufacture of liquids, creams and ointments 
 Annexure 10 – Manufacture of pressurised metered dose aerosol 
preparations for inhalation 
 Annexure 11 – Computerised systems 
 Annexure 12 – Use of ionising radiation in the manufacture of medicinal 
products 
 Annexure 13 – Manufacture of investigational medicinal products 
 Annexure 14 – Manufacture of products derived from human blood or 
human plasma 
 Annexure 15 – Qualification and validation 
 Annexure 16 – Organisation and Personnel 
 Annexure 17 – Parametric release 
 Annexure 18 – GMP Guide for active pharmaceutical ingredients 
 
Qualification and validation are integral parts of GMP and each pharmaceutical 
organisation has an obligation to adhere to these guidelines to remain compliant with 
the requirements for pharmaceutical manufacture and hence compliant with the 
Integrated Medicines and Related Substances Act 101 of 1965.   
 
Neal [7] states that validation was initiated in the 1960s but over the last thirty to forty 
years the understanding of the term has not improved.  He questions whether 
organisations and firms have embraced validation and states that validation has not 
received the recognition it deserves.  He declares that organisations are deriving little 
benefit due to lack of understanding of the process of validation.  He discusses thirteen 
remedies that can assist organisations to make validation more successful.  These are:  
1.4.1 Understanding.  Since drug manufacturers are compelled to perform validation, 
it is very important that the understanding be shared throughout the 
organisation and not alienated to the group responsible for performing 
Validation.  Neal states that firms derive little benefit if a thorough understanding 
of validation remains within the validation department, and there is absolutely no 
concept of the term within the department responsible for approving the 
validation budget.   
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Due to this lack of understanding; some of the following questions arise: “Why 
can’t the laboratory use a piece of equipment undergoing validation?  Why can’t 
the Facility be used before the laboratory has completed the analysis of the 
microbiological data?”  
 
1.4.2 Communication.  This is essential for any activity but more important in projects 
where activities require more than one resource. In another study Neal [8] 
emphasizes that effective communication can be improved by the project leader 
through information-sharing meetings with minutes capturing key points, the 
utilisation of numerous communication tools to share project status, and the 
provision of key updates.   
 
1.4.3 Experience.  Human resources with extensive experience are more productive 
than the occasional person practising validation.  The latter being people who 
have full time functions other than validation and who is occasionally involved in 
validation practices.  When using occasional validation practitioners as the chief 
resource, the deadlines for completion of the validation projects are normally not 
met. 
 
1.4.4 Cooperation and focus.  Each member of the validation team must be focussed 
on the overall task and willing to cooperate completely.  The Registrar of 
Medicine [9] states that validation is a GMP requirement and pharmaceutical 
manufacturers must identify validation work that is needed to prove control of 
critical steps of their operations.     
 
1.4.5 Resources.  This refers to personnel who will plan and execute validations on 
equipment, conduct laboratory analyses, etc.  Organisations often fall into the 
trap that regardless of how much knowledge, experience and understanding a 
company has of validation, if the proper resources for performing effective 
validation is not available, the deadlines will not be met. 
 
1.4.6 Budget.  Successful validation must be done to completion and the budgets to 
achieve this cannot be assembled by personnel who have no understanding or 
appreciation of how to successfully complete validation.  A rule of thumb is that 
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validation costs range between ten to twenty percent of the capital equipment 
costs.  Typically these charges relate to: 
♦ Investigating or acquiring information 
♦ Conducting meetings 
♦ Planning 
♦ Putting plans into words (protocols) 
♦ Executing plans 
♦ Troubleshooting and/or problem solving 
♦ Summarising the effort 
 
Many organisations do not plan for things to go wrong.  Validation is nothing more 
than checks upon checks.  During the validation process, trouble shooting and/or 
problem solving will be required with the necessary corrective actions.  This 
implies spending money.  It is essential that all costs, including validation of older 
equipment are reflected in the validation budget. 
 
1.4.7 Plan.  Any project must have a plan.  The Registrar of Medicine [10] states that 
the key elements of a validation programme should be clearly defined and 
documented in a validation master plan (VMP).  The validation programme 
should be coordinated by means of a formal policy document referred to as the 
validation master plan.  The (VMP) should at least include the following [10]: 
• Validation policy; 
• Organisational structure of validation activities; 
• Summary of facilities, systems, equipment and processes to be validated; 
• Documentation format: the format to be used for protocols and reports; 
• Planning and scheduling; 
• Change control; 
• Reference to existing document 
In cases of large projects, it may be necessary to create separate validation 
master plans or validation plans for major systems and processes. 
 
1.4.8 Training. 
Training is essential for any successful validation process and should not be 
overlooked. Training should not only include the writing and execution of 
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protocols.  In many instances, especially during testing of the functionality of the 
equipment, training in the operations of the system equipment is required to fully 
complete the validation protocols.  The validation project leader should initiate, 
coordinate, and facilitate training.  It is imperative that the training be 
documented in the form of training records as regulatory authorities requires 
proof of competency of personnel performing validation activities. 
 
1.4.9 Standard Operating Procedures (SOPs) 
Standard operating procedures (SOPs) capture activities that routinely occur in 
an organisation.  During the execution phase of validation, SOPs for set-up and 
operation for new equipment must be in place before certain stages of 
qualification can be signed off. 
 
1.4.10 Solid Quality Control support. 
During validations, laboratory testing is required which is mostly handled by the 
Quality Control (QC) Laboratory.  QC is expected to provide results in a timely 
manner to avoid delays with the validation effort.  Lack of support from this 
department can bring validation projects to a halt or cause unnecessary delays. 
 
1.4.11 Solid Quality Assurance support 
To meet all the relevant compliance issues, the Quality Assurance (QA) support 
is necessary to thoroughly oversee the protocols during and after execution.  
This is because QA is held accountable for compliance.  Resources selection 
should be the responsibility of the QA department.  Selecting the wrong people 
could hinder the validation effort and cause deadlines not to be met. 
 
1.4.12 Permission to conduct preliminary run. 
Just like any other new project/process or equipment, trials must be done to get 
to grips with the equipment.  Teething problems are normal and trial runs must 
be included in the validation budget.  In other words provision must be made to 
manufacture products that will be discarded.  
 
1.4.13 Realistic Completion dates. 
Many organisations fall into the trap of proposing unrealistic completion dates 
for validation. Typically the expectation is that once time is allocated to complete 
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three batches, the system/process under validation will be released and ready 
for use.  Unfortunately this is rarely the case.  For example cleaning validation 
activities will require time to complete the following activities: 
• Training 
• Selecting the correct sampling sites for the various equipment 
• Collecting cleaning samples (swabs and rinse samples) 
• Obtaining the microbial challenge results 
• Evaluating results and writing conclusions 
• Seeking and attaining post-execution approval  
The use of time management or project management tools (e.g. Gantt charts) is 
helpful in avoiding unrealistic targets.  If resource allocation is not done correctly 
and fewer resources are allocated than required (which is normally the case) 
the chances are that the environment will not be ready for validation, and as 
such the project deadlines will not be met. It is the responsibility of the validation 
leader to accurately plan, communicate, and realistically document the time 
required to complete the validation. 
 
In his study, Neal concludes that some of the thirteen remedies discussed may appear 
to be insignificant, but are all necessary for successful validation in organisations, and 
compliance with regulatory agencies.  He recommends that organisations perform a 
self-assessment and take the necessary steps to bring about improvements in the way 
validations are conducted.  The time required to bring about change is dependant on 
the interest and involvement of the executive and senior management team of the 
organisation.  
                                 
Within validation, there is another term used called “Qualification”.  Many people use 
these terms synonymously but there is a distinct difference.  The PIC/S Secretariat [11] 
states that it is internationally accepted that the term validation is often assumed to 
encompass the elements of equipment qualification, in addition to validation of the 
process itself.  This concept of qualification is not new as many suppliers have always 
performed checks to confirm functionality of their equipment against specifications both 
prior to and after installation.  However, documented records of the qualifications have 
to be kept which was always overlooked in the past.  The testing and checking was 
always done but not always documented.   The question now arises:  When and what 
do we qualify and validate?  Any aspect of the premises, the facility, the equipment or 
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the processes which may affect the quality of the product, directly or indirectly should 
be qualified and validated.  In summary, equipment, utility systems or facilities can be 
qualified but processes must be validated.  Figure 1 illustrates the interrelationships 
between qualification and validation. 
 
Figure 1 – Validation Activity Flow [11] 
 
 
 
Figure 1 illustrates the flow of activities related to qualification and validation.  Each 
stage of the Qualification must be completed before proceeding to the next stage.  It 
begins with the design specification.  The design qualification/specification looks at 
whether the equipment is designed to take into account the user requirements as well 
as requirements to meet good manufacturing practices (GMP).  According to the 
International Society for Pharmaceutical Engineering (ISPE) [12] there are some key 
factors to be considered for the equipment design qualification.  These include the 
following:  
• Does the design satisfy the GMP aspects or other regulatory requirements? 
• Does the design satisfy performance criteria? 
Installation Qualification 
Operational Qualification 
Process Validation or 
Performance Qualification 
Change Control 
Design Qualification/ 
Specification 
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• Does the design satisfy process flow, personnel flow, and preventing product 
contamination? 
• Does the design consider material of construction, cleaning, safety, and 
environmental impact? 
• Does the design consider start-up, shutdown, maintenance, and calibration? 
 
The design qualification is followed by the installation qualification. The installation 
qualification checks that all the equipment components are installed in the correct 
location, and as per drawings and specifications.  It also checks if the required utilities 
are available, and connected to the equipment correctly. The installation qualification 
must be completed, approved, and signed off before proceeding to the operational 
qualification.   
 
This operational qualification tests the functionality of the equipment.  It verifies that the 
equipment operate as per specification. This is normally the most tedious part of the 
qualification process as each function of the equipment must be tested across the 
operating range of the equipment.  The operating range must include at least three 
areas which are: 
• The minimum operating condition for the equipment; 
• The normal operating condition; 
• The maximum operating condition.   
The operational qualification is followed by the performance qualification or process 
validation. 
 
Process validation or performance qualification can be combined or separate.  This 
stage of the qualification checks the integration of other equipment or systems 
upstream and downstream in the process. It also checks the interaction of the 
equipment with the environment, and with the product.  Some organisations prefer to 
split Performance Qualification and Process Validation into two separate stages.  
According to the International Society for Pharmaceutical Engineering (ISPE) [13], 
performance qualification must not be confused with process validation.  Performance 
qualification (PQ) is the final step of the qualification process and only on completion of 
PQ should the process validation stage commence and not before. 
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This covers the qualification stages and the validation of the process.  However, during 
any stage of qualification, if changes are made, the impact of the changes must be 
assessed, authorised and documented.  If the change occurs after the qualification 
stage is completed, it could mean retesting or re-qualification depending on the nature 
of the change. For example, the equipment motor is changed after the design 
qualification and installation qualification have been completed.  If the new motor is not 
the same as the previous motor, the impact of the difference in the motor must be 
assessed and the installation and operational testing for replacing the motor must be 
repeated. Similarly if the process is changed, the extent of the re-validation or re-
qualification will be dependant on the change. 
   
An important part of the validation programme is to control changes.  After qualification 
and validation is completed, the challenge is to keep the equipment in a validated state.  
This can only be done with a formal change control programme in place.  It is essential 
that a change control programme is activated at the beginning of the qualification to 
capture all changes that occur during, and after the qualification and validation stages. 
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1.5 Definitions 
 
The International Society for Pharmaceutical Engineering (ISPE) [14] defines the 
terminology associated with validation as follows: 
  
1.5.1 Acceptance Criteria 
This is the predetermined result of a specified test. 
 
1.5.2 Cleaning Validation 
This is documented evidence that demonstrates that equipment is consistently 
cleaned from product, detergent and, in special instances, microbial residues 
to acceptable levels using standardized cleaning procedures.   
  
1.5.3 Critical Component 
This is a component within a system where the operation, contact, data, 
control, alarm or failure may have a direct impact on the quality of the product. 
 
1.5.4 Design Qualification 
According to the PIC/S Secretariat [15], design qualification constitutes 
documentary evidence that the premises, the supporting utilities, the 
equipment and the processes have been designed in accordance with the 
requirements for good manufacturing practices. 
 
1.5.5 Direct Impact 
These are systems and/or equipment that are expected to have an impact on 
product quality. 
 
1.5.6 Efficacy 
The effectiveness of a product to do what it is intended to do. 
 
1.5.7 Enhanced Design Review 
This is a documented review of the design of a system and/or equipment for 
conformance to operational and regulatory expectations.  
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1.5.8 Factory Acceptance Tests (FATs) 
These are inspections or testing of systems or system components to support 
the qualification of an equipment system conducted and documented at the 
supplier site. 
 
1.5.9 Functional Specifications 
These are detailed descriptions of the logical operations and functions of the 
equipment/systems, the operating ranges, precautions, and conditions of the 
equipment/systems. 
 
1.5.10 Good Engineering Practices (GEP) 
These are established engineering methods and standards that are applied 
throughout the project lifecycle to deliver appropriate, cost-effective solutions. 
 
1.5.11 Good Manufacturing Practices (GMP) 
These are guidelines compiled by the government regulatory authority in the 
form of a recognised document(s) defining the necessary practices for the 
manufacture of medicines. Due to the continuous improvements to the 
guidelines, it is referred to as current Good Manufacturing Practices or 
abbreviated as cGMP. 
 
1.5.12 Indirect Impact 
These are systems and/or equipment that are NOT expected to have an 
impact on product quality. 
 
1.5.13 Installation Qualification 
This is documented verification that all aspects of a facility, utility or equipment 
that can affect product quality adhere to approved specifications (e.g. 
construction, materials) and are correctly installed.  The PIC/S Secretariat [15] 
defines the Installation Qualification as documentary evidence that the 
premises, the supporting utilities, the equipment and the processes have been 
built and installed in compliance with their design specifications. 
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1.5.14 Operational Qualification 
This is documented verification that all aspects of a facility, utility or equipment 
that can affect product quality operate as intended throughout all anticipated 
ranges.  According to the PIC/S Secretariat [15], the Operational Qualification 
is documentary evidence that the premises, the supporting utilities, and the 
equipment operate in accordance with their design specifications. 
 
1.5.15 Performance Qualification 
This is documented verification that all aspects of a facility, utilities and 
equipment that can affect production quality, perform as intended to meet 
predetermined acceptance criteria. 
 
1.5.16 PIC/S [16]. 
The Pharmaceutical Inspection Convention and Pharmaceutical Inspection 
Co-operation Scheme (jointly referred to as PIC/S) are two international 
instruments between countries and pharmaceutical inspection authorities, 
which collectively provides an active and constructive co-operation in the field 
of GMP. 
 
1.5.17 Process Validation 
This is establishing documented evidence that provides a high degree of 
assurance that a specific process will consistently produce a product meeting 
its pre-determined specifications and quality attributes. 
 
1.5.18 Protocol 
This is a document that describes the system under consideration, the test 
plans, the acceptance criteria and the test results that ensure that a system is 
installed, operates, and performs according to predetermined specifications. 
 
1.5.19 Qualification 
The action of proving and documenting that equipment or systems are 
properly installed, work correctly, and actually lead to the expected results.  
Qualification is part of validation, but the individual qualification steps alone do 
not constitute process validation.  It also includes the approach in assessing 
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the level and extent of testing that will be performed on equipment or ancillary 
systems before they are used to manufacture products. 
 
1.5.20 Site Acceptance Tests (SATs) 
These are inspections or testing of systems or system components to support 
the qualification of an equipment system conducted and documented at the 
manufacturing site. 
 
1.5.21 User Requirement Specification 
This is a list of the requirements that the equipment or services must meet to 
manufacture products at required throughputs, and under specific conditions. 
 
1.5.22 Utilities 
These are services or systems that have either a direct or indirect impact on 
the quality of the manufactured product.  They include water, purified water, 
heat ventilation and air-conditioning, dust extraction, house vacuum, chilled 
water, electricity, steam, compressed gases, access control and security, fire 
services and alarms, and building management systems.   
 
1.5.23 Validation 
Validation is documented evidence of a high degree of assurance that a 
system functions consistently, in the way it is intended whilst meeting 
predetermined criteria. 
 
1.5.24 Validation Master Plan 
The “Validation Master Plan” is a high level document, which establishes an 
umbrella plan for the entire validation project and is used as a guide for 
resources and technical planning.  According to the PIC/S Secretariat [15] a 
Validation Master Plan is a document that summarises the firm’s overall 
philosophy, intentions and approach to be used to establish adequate 
performance.  
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CHAPTER 2: EQUIPMENT AND UTILITIES 
 
 
2.1 Introduction 
 
Various phases of the project must be completed during the erection of a new 
pharmaceutical plant, before manufacture of product can commence.  These include 
the commissioning phase, the qualification, and validation phase.  The commissioning 
phase occurs after completion of the building. The ISPE [17] states that the 
commissioning and qualification activities play a crucial role in delivering operationally 
effective, safe and efficient facilities, utilities, equipment, and processes.  It is the 
foundation upon which process validation is built.  It is therefore imperative that a 
comprehensive approach is undertaken during the commissioning and qualification 
phases.  In other words qualification of the equipment, utilities and any direct impact 
services must first be completed before manufacture of pharmaceuticals can 
commence.   
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Figure 2 – Scope of Commissioning and Qualification [17] 
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Figure 2 illustrates the ISPE approach to commissioning and qualification, and how 
these stages are integrated.  The engineering change management occurs from the 
start of the project.  Changes during the design phase must be controlled and 
managed.  The design development is the design phase of the project.  This includes 
initial draft drawings whilst the project is still at the concept phase.  The enhanced 
design review is the first form of documentation structure with all the available 
documents in its final form.  Impact assessment begins at the start of the design 
development and enhanced design review stage.  After completion of the design 
phase all documentation should be in place.  The equipment or system can now be 
purchased. Once this has been formalised the testing stages commence.  Functionality 
checks are performed at the supplier’s site first and on successful completion, the 
equipment is delivered to the customer’s site.  Aspen OSD selected this option for 
most equipment that was already purchased, and continues to follow this approach.   
 
Factory acceptance tests and site acceptance tests documents are purchased from the 
supplier, executed, and referenced in the validation protocols. Project teams consisting 
of personnel from validation, quality assurance, and production departments visit the 
different suppliers and test the equipment at the supplier site before shipping the 
equipment to Aspen OSD. Problems encountered with the equipment during this stage 
of testing, is sorted out by the supplier before the equipment is transported to Aspen 
OSD.  The major advantage of this approach is that the equipment that arrives at 
Aspen OSD has been tested thoroughly.  Another advantage is that once the 
equipment arrived at Aspen OSD, only about twenty percent of testing need be 
repeated since one hundred percent testing was already done.  The testing done at the 
Aspen OSD site would be documented as the “Site Acceptance Tests” or SATs. The 
tests to be repeated at the Aspen OSD site are carefully selected.  Parameters or 
conditions that may change during transit of the equipment from the supplier’s site to 
the Aspen OSD site will be selected for retesting. Standard tests like instrument 
calibrations are generally included in the SATs. 
 
The testing discussed above falls under the commissioning phase.  Qualification and 
validation overlaps with the commissioning phase where certain qualification/validation 
testing is done in the commissioning phase for validation purposes.  However, the 
documentation systems and procedures necessary for validation must be followed, 
e.g. if the equipment is a big granulator with two big motors attached.  The functionality 
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of the motors can only be tested while the equipment is being installed and before the 
safety covers and panels are installed permanently. If the qualification/validation 
testing is not done at this stage, checking the functionality of the motor later will not be 
practical as all the safety covers and panels will have to be removed in order to 
perform the testing.  If qualification/validation testing is done at a later stage work will 
be duplicated since the operational checks of the motors must be done during the 
commissioning phase.  In this case, the testing done during the commissioning phase 
is referenced in the validation documents.  In this way the testing is performed 
according to procedures and the results are suitably documented for validation 
purposes. 
 
The separation of the direct and indirect impact systems during the impact assessment 
is very necessary to prevent duplication of work and to limit the quality related aspects 
of the equipment to validation, and the mechanical and operational related aspects of 
the equipment to commissioning.   
 
Figure 2 shows those components of the validation process that compliance 
regulators are most interested in namely the enhanced design review, installation 
qualification (IQ), operational qualification (OQ), performance qualification (PQ), and 
process validation. 
 
The ISPE approach [18] is to separate the good engineering practices in the 
commissioning phase from the qualification and validation practices which affects the 
quality attributes of the product.  Indirect impact systems can simply be commissioned 
but direct impact systems must be qualified and validated after commissioning.   The 
Aspen OSD approach followed the ISPE approach. 
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Figure 3 – Relationship between Direct, Indirect and No Impact” systems [19] 
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Figure 4 – System impact assessment overview [20] 
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Figure 4 illustrates the steps used to determine the nature of impact assessments of 
equipment and systems. Vincent and Honeck [21] state that impact assessment 
identifies the systems that could present a risk to the product quality if improperly 
designed or installed.  They also stress that organisations can decrease the cost and 
time to perform system qualifications by spending time upfront in performing risk 
assessment which will save the company time and money in the long run since 
unnecessary systems will not be qualified but only commissioned.  Risk assessment 
programmes will help to ensure that the final product quality is achieved.  
 
According to Neal [22], the lead validation resource (project manager) is responsible to 
accurately plan, communicate, and realistically reflect the time required to complete 
validation.  This can be successfully done by using the project management approach.  
According to the Registrar of Medicine all validation activities should be planned and 
documented in a “Validation Master Plan” [10].  Thus before the validation project can 
commence, a validation master plan (VMP) document must be compiled that defines 
the organisation’s intent and approach to validation, and the extent to which validation 
will be performed.  Guidelines for the compilation of a VMP are available from the 
various regulatory authorities.  Aspen OSD owns a VMP that declares the approach, 
extent and commitment to validation, taking into account the regulatory guidelines.   
 
Thiesset [23] states that a validation plan does not necessarily need to be an all-
encompassing 100-page document but a concise document that clearly states the 
project’s purpose, the validation approach, and the overall acceptance criteria.  He 
stresses that a validation project plan should be developed which serves as the road 
map to ensure that each required task has been executed as planned. 
 
The Aspen OSD approach has been to separate the Aspen OSD facility into 
departments, and compile individual validation plans for each department.  There are 
validation plans for complex systems viz. purified water, and heat, ventilation and air-
conditioning (HVAC).  All equipment related to a specific department is included in the 
relevant validation plans.  The following validation plans have been compiled for Aspen 
OSD: 
♦ VP101 – Utilities  
♦ VP102 – Dispensary 
♦ VP103 – Granulation 
     - 25 - 
♦ VP104 – Compression and Coating 
♦ VP105 – Packing 
♦ VP106 – Warehouse and Sampling  
♦ VP107 – Purified Water  
♦ VP108 – Heat, Ventilation and Air-Conditioning (HVAC) 
♦ VP109 – Cleaning Validation 
♦ VP110 – Process Validation 
 
Each validation plan contains an Impact assessment where the equipment or systems 
are classified into direct impact or indirect impact equipment or systems.  Each 
validation plan contains the validation documentation (protocols and reports) required 
to complete that specific validation plan.  The nomenclature for naming the various 
validation plans, protocols, and reports is described in the Aspen standard operating 
procedure QV001 – Control of Validation Documents [24].  For a template of a 
validation plan refer to Appendix 1.  Whenever new equipment is purchased, the 
validation plan is amended through the change control System. The amended 
validation plan will contain the relevant impact assessments as well as the validation 
documentation sections which are amended to reflect the protocols required and the 
extent of validation of the new equipment. 
 
The remainder of this chapter will discuss the different stages of qualification (DQ, IQ, 
OQ & PQ) of two aspects of Aspen OSD viz the facility qualification, and the heat, 
ventilation and air-conditioning (HVAC) system qualification.  The problems identified 
for the various stages of qualification with proposed solutions will be discussed. 
 
2.2 Design Qualification 
 
Before any qualification stage can commence, the necessary preparations and 
planning should be in place.  As mentioned before, a validation master plan together 
with specific validation plans must be available.  In addition other documentation in the 
form of qualification protocols must also be available prior to testing.  Protocols must 
be compiled, reviewed and approved before testing can commence.  The compilers of 
the protocols must have knowledge of the equipment or system therefore the 
information to compile the protocols must be available to the compilers.  The scope of 
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the protocols and the level of testing will be related to the complexity of the equipment 
and the critical nature of that equipment on the quality of the final product [25]. 
 
The design qualification is the first stage of the qualification of the equipment or 
system.  It will detail the preliminary activities that occur prior to the equipment arriving 
on the premises.  According to PIC/S Secretariat [26] the purpose of the design 
qualification is to ensure that the premises, the supporting utilities, the equipment and 
the processes have been designed in accordance with the requirement of good 
manufacturing practices.   According to the Registrar of Medicine [27] the first element 
of the validation of new facilities, systems or equipment could be design qualification 
(DQ).  The ISPE [28] states that the FDA does not require a design qualification for 
equipment/systems in the validation project.  The design qualification is therefore not a 
regulatory requirement.  The ISPE adopted an approach defined as the “Enhanced 
Design Review”.  This is good engineering practice and the smart way to prepare for 
installation and operational qualification.  The design of the pharmaceutical facility, 
systems and equipment are evaluated separately and integrated to ascertain whether 
good manufacturing practices have been taken into account. 
 
Figure 5 – V-model for Direct Impact systems [29]. 
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Figure 5 is the V-model approach for direct impact systems.  Documentation of all the 
components to the left of the vertical line is required for enhanced design review 
(EDR).  The EDR will review the user requirement specifications or user briefs and 
compare the functional and design specifications of the equipment to see if all the user 
requirements will be met. The inspection up to this stage is purely documentary.  
Drawings related to the system will be evaluated to ascertain if user requirements will 
be met.  Drawings may include: 
♦ Layout drawings (dimensions of equipment and positioning); 
♦ Piping and Instrumentation Diagrams [P&IDs] (overview of system process flow); 
♦ Electrical drawings (overview of electrical connections); 
♦ Pneumatic drawings(overview of pneumatic connections); 
♦ Temperature and relative humidity drawings (overview of conditions ); 
♦ Differential pressure regime drawings (overview of conditions); 
♦ Utility drawings (overview of where utilities are required); 
♦ Material of construction certificates (e.g. stainless steel grade ASTM 316); 
♦ Material and personnel flow (overview of material and personnel movement); and 
♦ Room data sheets (overview of room dimensions and utilities required). 
 
The Aspen OSD approach involves following the Aspen standard operating procedure 
GE007 – Qualification of Equipment and Utilities [30]. This is very similar to the 
enhanced design review promoted by the ISPE.  Design review protocols are compiled 
and approved prior to testing.  For a template of the design review protocol refer to 
Appendix 2.   
 
The design review protocols are then executed and five standard tests are done and 
documented in the test data sheets (TDS).  These are: 
¾ TDS1 Documentation Review; 
¾ TDS2 User Requirement Specification Check; 
¾ TDS3 Identification of Direct Process Relevant Parts; 
¾ TDS4 Identification of Critical Devices; and 
¾ TDS5 Identification of Utilities 
2.2.1 TDS1 – Documentation Review 
This test verifies that all documentation relating to the system is available.  
The correct versions/revision numbers of drawings (listed above) are 
especially important as drawings change from design to the “As Built”.  The 
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correct drawings must be documented as all other subsequent testing will be 
done with the version/revision numbers defined in the design review.  
Documents like the functional specifications, user requirement specifications; 
equipment certificate (e.g. pressure vessel test certificates, material 
certificates of product contact parts, noise level certificates, fan motor 
certificates, etc.), calibration certificates, factory acceptance test protocols and 
reports, site acceptance test protocols and reports, operating and 
maintenance manuals, spare parts lists are checked for availability.  If the 
system has a control panel or programmable logic controller (PLC), the 
software discs, CD-ROM discs, and input/output diagrams are checked for 
availability.   
 
All documentation related to this test is submitted and recorded in a document 
register where a unique number is allocated and filed in a secure location.   
 
2.2.2 TDS2 – User Requirement Specification Check 
This test extracts a list of the key requirements from the user requirement 
specification or user brief.  The functional specification of the equipment is 
checked against the list of key requirements to ascertain if the requirements 
have been met.  If deficiencies are present, a list of deficiencies is compiled.  
Deficiencies are classified as deviations and dealt with accordingly.  See 
pages 29 & 30; Failures accepted with Justification and Failures accepted 
Corrective Action below. 
 
2.2.3 TDS3 – Identification of Direct Process Relevant Parts 
This test involves isolating the components of the equipment that can 
influence the outcome of the product. The functional specification and process 
and instrumentation diagrams (P&ID) are checked with engineering guidance.  
The components that will affect the operations of the equipment will be 
identified and listed.  This list is used to check the installation and operation of 
the components in the qualification stages to follow.  The Aspen definition of a 
direct process relevant part is “all calibrated sensors; all product or material 
contacting parts and all process gas contacting parts, if they are not separated 
from the product by a filter (e.g. HEPA or product filter)”. 
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2.2.4 TDS4 – Identification of Critical Devices 
This test is a subset of the list compiled in TDS3.  A “Critical Devices” list is 
compiled.  Critical devices are all sensors, meters, components, and gauges 
that can be calibrated.  As a rule-of-thumb all critical devices must be direct 
process relevant parts but not vice-versa.  This is important as these devices 
must be included on the factory calibration schedule. The Aspen definition of 
Critical Devices is “devices within a system where the operation, contact, data, 
control, alarm, or failure may have a direct impact on the quality of the 
product.  All critical devices are a subset of the direct process relevant parts of 
a system”. 
 
2.2.5 TDS5 – Identification of Utilities 
This test identifies the utilities that must be available for the equipment before 
installation.  The functional specification as well as the P&ID is checked to see 
which utilities and services must be required.  For example if the equipment 
runs on 3 phase, 440 volts, 50 Hz electricity, a suitable outlet must be 
available at the place where the equipment will be installed.  If purified water, 
dust extraction or any other utility is required in the room then these must be 
available in the room. 
 
Tests from a specific test data sheet can only have a “Pass” of “Fail” status.  Should 
only one test in the entire test data sheet fail, the overall outcome for that specific test 
data sheet is “Fail”.  A failure can be treated in two ways; either the failure is accepted 
with a suitable justification or corrective action is initiated to fix the failure and the test 
is repeated after the corrective action is completed.  In either case, a deviation is 
raised and the Aspen Standard Operating Procedure GE002 – GMP Deviations is 
followed [31].  Below are examples of failures that have been accepted with 
justification in Aspen OSD.   
 
Failure accepted with Justification 
TDS2 – User Requirement Specification Check.  One key user requirement specified 
for the “Roller Compactor Chilsonator” (a specific granulator) was that the electronic 
control panels must be a specific make, Siemens.  Siemens control panels were 
specified for consistency to reduce inventory cost for spare parts. This supplier 
provided a different make electronic control panel, Telemacanique.  There are no 
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adverse effects on the operations of the equipment by using the different make of 
electronic control panel, but the test fails.  In this case a deviation is raised and the 
failure is accepted with an explanation authorised by the Engineering, Production and 
Quality Assurance managers.   
 
Failure accepted with Corrective Action 
TDS2 – User Requirement Specification Check.  One key user requirement specified 
that the fan motor power for the air handling unit of the heat ventilation and air 
conditioning (HVAC) is 75 kW to deliver 17.73 m3 of air per second in order to ensure 
that the specified air change rate is maintained in the production rooms.  The 
functional design specification stated a fan motor power of 65 kW, a clear failure.  
Corrective action is required to replace the fan motor with the one specified.  The 
deviation will therefore specify the corrective action, the responsible person or 
department head, and the time of completion.  The installation qualification testing will 
therefore not proceed until the fan motor is replaced.   
 
In some instances the required corrective action called for changes in the design of 
the equipment or system.  In the case of the HVAC system, the casings of the air 
handling units did not account for the pressure build-up inside the air handling unit 
during operations.  The design flaws of the air handling unit casings were investigated 
and changed via the documented change control system as per Aspen procedure 
GE003 - Management of Change Control [32].  This was done for all the air handling 
units and not only the ones that burst open during operation.  
 
On completion of the design review protocol, the results are summarised in a design 
review report.  The design review report includes tabulation of the overall status of 
each test data sheet with either “Pass” or “Fail” status.  The design review report will 
reference any documentation used during the execution of the protocol, all deviations 
and Corrective actions required and time lines for their completion.  The design review 
stage of the qualification is then authorised and approved. The installation qualification 
and the design review protocols can be executed concurrently. 
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2.3 Installation Qualification 
 
The ISPE [33] states that the purpose of the installation qualification is to establish 
that the critical components are installed correctly and in accordance with the design 
documentation requirements (i.e. specifications, purchase order, contracts, etc.) and 
the purpose of the installation qualification protocol is to record the checks and 
verifications required for these critical components. 
 
The Aspen OSD approach for installation qualification was twofold.  In the case of the 
complex equipment, the supplier’s “Factory Acceptance Tests” (FATs) and the “Site 
Acceptance Tests” (SATs) documents were purchased with the equipment.  The FATs 
were done at the supplier site and the SAT at the Aspen OSD site.  The installation 
qualification (IQ) protocol integrated the commissioning part with the IQ as the testing 
performed in the SATs was referred to in the IQ protocol. 
 
The general Aspen OSD approach for installation qualification was to perform tests on 
the Direct Process relevant parts list (TDS3) of the design review protocol.  For a 
template of the installation qualification protocol, refer to Appendix 3.   
 
The HVAC Installation Qualification protocol typically contains the following tests:  
 
2.3.1 TDS1 – Mechanical component installation checks 
• System Instrumentation checks.  The Piping and Instrumentation Diagram 
(P&ID) is literally “walked through” to verify that all the instrumentation 
(e.g. sensors, meters, gauges, screens, and dials) is installed in the 
correct place relative to each other, and as per the equipment drawings. 
• Installation component checks. This test checks if all the direct process 
relevant parts (TDS3 – Design Review protocol) are installed as per 
equipment drawing. It also verified that the components and sub-
components are labelled correctly, and that the component specifications 
are as per the equipment drawings.  For example if the motor capacity, the 
cooling coil capacity, and the sensor details are as per the specifications. 
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2.3.2 TDS2 – Pneumatic component installation checks 
This test verifies that all the pneumatic components are installed in the correct 
place, and as per the equipment pneumatic drawings for the direct process 
relevant parts. 
 
2.3.3 TDS3 – Electrical component installation checks 
This test verifies that all the electrical components are installed in the correct 
place, and as per the equipment electrical drawings for the direct process 
relevant parts. 
 
2.3.4 TDS4 – Identification of Standard operating procedures 
This test identifies the operation, maintenance, and calibration procedures that 
must be available at the end of the operational qualification.  Aspen OSD 
document numbers are allocated for the various procedures and the relevant 
personnel are notified to compile the procedures. 
 
2.3.5 TDS5 – Including equipment on Maintenance and Calibration schedule 
This test verifies that the critical devices from TDS4 – Design Review protocol, 
are included on the Aspen calibration schedule. 
 
On completion of the installation qualification protocol, the installation qualification 
report is compiled and approved referencing all the documentation (protocols, 
deviations, change controls, and outstanding actions) used during the completion of 
the installation qualification. 
 
2.4 Operational Qualification 
 
The ISPE [34] states that the purpose of the operational qualification is to establish 
through documented testing, that all critical components and “Direct Impact” systems 
are capable of operating within established, limits and tolerances. 
 
The Aspen OSD approach for operational qualification was similar to the installation 
qualification. Testing completed during the FAT and SAT was integrated and 
referenced in the OQ protocol.  For a template of the operational qualification protocol 
refer to Appendix 4.   
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The Operational Qualification protocol typically contains the following tests:  
2.4.1 TDS1 – Calibration of Critical Devices 
This test verifies that the critical devices as per TDS4 – Identification of Critical 
Device from the design review protocol have all been calibrated.  This test can 
be done during the execution of the OQ protocol or before any operational 
testing commences depending on the equipment or system. For example 
devices measuring temperature, relative humidity and differential pressure must 
first be calibrated before any readings can be taken for the operational testing.  
However, there are exceptions; for example, the roller gap for a Roller 
Compactor granulator will be calibrated during the site acceptance tests at the 
supplier site.  After the installation qualification is completed, the calibration will 
be repeated but only after a few operational tests have been done. 
 
It is also very important that any instruments used for performing measurements 
during testing in the operational qualification are calibrated with valid calibration 
certificates.  Problems are often encountered with invalid calibration certificates 
for instruments used to perform tests.  Generally this is only discovered once 
the documentation have been reviewed and checked at the end of the process.  
Re-testing with calibrated equipment can then cause unnecessary delays. 
 
2.4.2 TDS2 – Availability of Standard Operating procedures 
This test verifies that the procedures identified as per TDS4 – Identification of 
standard operating procedures from the installation qualification is approved 
and available.   
 
2.4.3 TDS3 – Verification of personnel training 
This test verifies that the relevant personnel know how to operate the equipment 
and that the training has been completed. For complex equipment, a supplier 
representative will normally provide the training.  Alternatively, the subject 
matter expert who is normally the compiler of the procedure will perform the 
training. Training normally contains both a theoretical and competency 
assessment component. Copies of the training records are included as 
evidence of the completed training.  
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2.4.4 TDS4 – Operational checks of equipment Functionality 
This test verifies the operations of each of the direct process relevant parts that 
were checked during the installation qualification. Testing confirms that the 
equipment can sequence through its operating steps and those key process 
parameters or functions are thoroughly checked to ensure compliance with 
operating specifications [35].   
 
A very important operational test is verifying that the equipment and 
components operate throughout the operating range. For example, the tableting 
machine (Rotary Tablet Press):  If the specification for the tablet making speed 
is 500 to 2000 tablets per minute, the testing must verify that the machine can 
compress tablets throughout the range of 500 to 2000 tablets per minute.  So 
often this is overlooked and testing is done at the normal operating condition 
only.  This may lead to problems and unnecessary delays when the equipment 
is used in production outside of the normal operating ranges. 
 
2.4.5 TDS5 – Start-up, Shutdown and Emergency checks 
These tests verify that the equipment start-up and shut down under normal 
operations, and whenever an emergency occurs.  These are critical test to 
ensure operator’s safety. 
 
2.4.6 TDS6 – Alarm and Interlock checks 
This test verifies any other safety or other alarm tests if an abnormal condition 
occurs.  During testing, alarm conditions are simulated to check if the various 
alarms and interlocks of the equipment operate as per specification.  
 
2.4.7 TDS7 – Power failure and recovery checks 
This test verifies that the correct sequence of events takes place as per the 
design should a power failure occur.  Once again the power failure will be 
simulated and the power recovery events will be checked to ascertain if the 
equipment operates as per specification. 
 
Similarly to the installation qualification, once the operational qualification protocol is 
completed, the operational qualification report is compiled and approved before the 
performance qualification commences. 
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2.5 Performance Qualification 
 
The ISPE [36] states that the purpose of the performance qualification is to integrate 
procedures, personnel, systems and materials to verify that the pharmaceutical grade 
utility, environment, equipment and support system produces the required output. 
 
The Aspen OSD approach for operational qualification was similar to the installation 
qualification. Testing completed during the FATs and SATs was integrated and 
referenced in the OQ protocol. For a template of the Performance Qualification 
protocol refer to Appendix 5. 
   
The performance qualification protocol will be specific for the equipment or system.   
According to the PIC/S Secretariat [37] there are key parameters that must be 
controlled and included in the qualification of the HVAC.  These parameters include:  
i) Temperature (since high or low temperature can have serious effects on the quality 
of the ingredients or the final product); 
ii) Relative Humidity (as some products must be manufactured under strict relative 
humidity control); 
iii) Air flow direction (controlled by differential pressure) (to prevent cross 
contamination with another product that is manufactured in the adjacent room); 
iv) Air filtration (since the air is in direct contact with the ingredients and the final 
product, and must be clean); and 
v) Air change rate (for the containment of dust.  Pharmaceutical processes have dust 
generating steps viz. sizing, milling and drying).  The dust must be removed rapidly 
to avoid cross contamination). 
 
The HVAC system will typically contain the following tests: 
2.5.1 TDS1 – Completion of Installation and Operational Qualifications 
This test verifies that the Installation and Operational Qualification Reports are 
available and approved.  It also verifies that: 
• All major deviations have been completed; 
• All major change controls have been completed; and 
• All procedures and instructions are available where required. 
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2.5.2 TDS2 – Production room Temperature checks,  
This test verifies that the temperatures within the production rooms are within 
specification.  The temperature is measured at different points in the room over 
a 5 day period.  In this way the temperature is mapped within the room and a 
five point temperature profile is obtained to check if the temperature condition 
throughout the room is within specification.  The temperature specification for 
the Aspen OSD facility is 19°C to 23°C 
   
2.5.3 TDS3 – Production room Relative Humidity checks 
This test verifies that the relative humidity within the production rooms is within 
specification.  Similar to TDS2, a five point relative humidity profile is obtained 
for each production room. The relative humidity specification for the Aspen OSD 
facility is: “Not more than 55% RH”. 
 
2.5.4 TDS4 – Production room Differential Pressure checks 
This test verifies that the differential pressures within the production rooms are 
within specification.  The differential pressure ensures that the airflow direction 
is maintained and as per the design specification.  This test is supported by an 
operational qualification test which verifies the air flow direction.  Smoke is 
generated outside each room and the direction of the smoke movement is 
visually observed and checked versus the specification.  In some instances the 
smoke direction is video taped as evidence of the air flow direction. 
 
2.5.5 TDS5 – Production room Particle Count checks 
This test verifies that the number of airborne particles present in the air within 
the production rooms is within specification.  According to the Registrar of 
Medicine [38] there are different specifications for different areas.  See Table 1 
below. 
Table 1 – Airborne particulate classification [38] 
 At Rest In Operation 
Grade of Air Max permitted number of particles/m³ 
Particle size 0,5 µm 5 µm 0,5 µm 5 µm 
A 3 500  1** 3 500 1** 
B 35 000  1** 35 000 2 000 
C 350 000 2 000 350 000 2 000 
D 3 500 000 20 000  Not defined Not defined 
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** These areas are expected to be completely free from particles of size greater 
than 5 µm.  As it is impossible to demonstrate the absence of particles with any 
statistical significance, the limits are set to 1 particle / m3. 
 
2.5.6 TDS4 – Production room air change rate checks 
This test verifies that the air change rates in the production rooms are within 
specification.  This is done by measuring the exhaust air volume and calculating 
the air changes per hour as follows: 
 
Air Change Rate (ACR) per hour = Exhaust air volume (m3/second) x 3600 (seconds/ hour) 
 Room volume (m3)  
 
Another example of a performance qualification study was that of the drying oven.   
The PQ for the drying oven differed slightly to the PQ for the HVAC system.  A batch of 
product is dried in the oven and the moisture determined on the dried product.  The 
test data sheets for the drying ovens include the following: 
 
• TDS1 – Completion of Installation and Operational Qualifications.   
This is the same as 2.5.1 above. 
 
• TDS2 – Setup parameters for the Oven.   
This test verifies that the actual parameters of the oven during the drying process 
are the same as the drying recipe for the product.  It also acts as an audit 
checklist to verify that the operator uses the correct parameters and operates the 
oven in the correct manner. 
 
• TDS3 – Moisture Determination.    
This test verifies the moisture content of samples taken at different positions and 
compares the results to the moisture specification of the product.  
    
All of the above testing is done on 3 successive batches of the same product. 
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2.6 Problems and associated problem solving 
 
The problems and problem solving for each phase of the qualification process is 
discussed below. 
 
2.6.1 Design Review problems  
There was no design qualification done for the equipment and systems.  
However, complex equipment was purchased from experienced European 
suppliers (i.e. suppliers who have been in the pharmaceutical manufacturing 
business for many years) and personnel who had knowledge of the 
requirements of validation.  The design review protocols at least ensured that 
the GMP aspects of the equipment or systems had been reviewed and checked.  
 
The user requirement specification (URS) was not detailed enough regarding 
requirements for the equipment.  The user requirement specification contained 
contractual information with the equipment suppliers but not enough information 
regarding performance of the equipment or systems.  During the design review 
qualification, one of the tests required that key requirements from the URS be 
compared to the functionality of the equipment to determine the extent of the 
match.  It was difficult to extract the key requirements from the URS since there 
was too much “other” information specified in the URS.  There was no easy 
solution to this problem.  A combination or production and engineering 
personnel was seconded to assist in identifying key requirements.  
 
During the execution of the design review of the HVAC systems, the main 
problems were associated with the drawings.  The revision numbers were 
defined correct in the design review protocol.  However, the HVAC drawings 
were constantly changed and there were huge time delays in obtaining the 
updated revisions.  By the time the latest revisions were available, more 
changes had already been made; therefore the latest revisions were outdated 
as soon as these were received.  This was mainly due to a lack of change 
control during the commissioning phase.  Other changes to the HVAC system 
were also not very well controlled.  Figure 1 clearly defines that engineering 
change management must start with the design phase.  Even though the 
decision making for the changes followed sound engineering practices and 
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reasoning, the authorisations of the changes were not official since no official 
change control was exercised.  Technically the changes were unofficial and 
unapproved and hence not in line with good engineering practices.  The net 
result for the HVAC design review protocol was that the “As Built” drawing 
revision numbers listed in TDS1 was not the same revision numbers used to 
perform checks in the subsequent installation qualification.  The lack of change 
control during commissioning was remedied by training the affected personnel, 
and enforcing the existing change control system. 
 
There was a misunderstanding of the terms “direct process relevant part” and 
“critical devices”.  Initially the Aspen OSD engineering team only consisted of a 
project engineer and one process engineer.  The engineering interpretation of 
“critical device” or a “direct process relevant part” of the equipment was not very 
clear.  This caused changes upon changes which delayed the completion of the 
installation and operational qualification phases.  This problem was remedied by 
the relevant parties brainstorming the definition so that everybody clearly 
understood the direct process relevant parts and critical devices for different 
equipment. 
 
2.6.2 Installation Qualification problems 
In the case of the HVAC system, there were no official factory acceptance test 
(FATs) or site acceptance test (SATs) documents purchased.  The equipment 
was specially designed by consulting engineers for the Aspen OSD building.  
The consulting engineers were not very experienced in the principles of 
validation or qualification and thus no documentation was received upfront even 
though validation was specified in the user requirement specifications.  The 
problem was remedied by employing a project specialist who assisted with the 
installation, commissioning and overall qualification of the system.  
 
Another problem with the HVAC Qualification was the unavailability of protocols.  
The commissioning phase was about 60% completed before the first HVAC 
protocol was approved.  Due to this the qualification testing was done over a 
period of about nine months.   Since HVAC is a dynamic system, testing done 
two months ago for a particular area was not the same two months later, and 
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this created a problem.  Seeing that all the areas are interrelated, the effects on 
adjacent areas meant that the results were questionable. 
   
2.6.3 Operational Qualification problems 
The impact of room doors opening and closing especially during testing of the 
HVAC system had an effect on the results.  During the commissioning phase, 
there were many activities occurring simultaneously and the continuous traffic 
through the doors affected the test results.  For example when the supply air 
flow and the exhaust air flow was measured in one room, and a room door was 
opened or closed further down the passage, the accuracy of the measurement 
was questioned. The problem was remedied by taking a series of 
measurements at different times to reduce the measurement errors.   
 
Another important point was all the adjustments made during commissioning, 
especially if initial readings were out of specification. Corrective actions were 
implemented which influenced the previous testing, but measurements were not 
redone after the corrective actions were implemented. This problem was noticed 
during the execution of the operational qualification. This was remedied by 
repeat measurements of all the rooms after all corrective actions were 
completed.   
 
During commissioning after the air handling units were operating for a while, the 
joints between the casing of two air handling units ruptured and the units were 
blown apart due to the pressure build-up inside the units.  This was due to a 
design flaw of the air handling casing.  The design of the casing was thus 
changed, and the casing was re-enforced to withstand greater pressure.  The 
casing design was improved by installing pressure relief panels to relieve the 
pressure inside the units before reaching the maximum pressure conditions.  The 
air handling unit casing design change was documented via the change control 
system and implemented in all the air handling units and not only the affected 
ones. 
 
The “As built” room dimensions were different to the design dimension which 
affected the air change rate.  This factor was not taken into account with the 
initial commissioning and the designed supply and exhaust volumes were not 
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adjusted.  This resulted in some rooms having air change rates of greater than 
30 changes per hour whilst other rooms were below the specification of 15 air 
changes per hour.  This was remedied by balancing and re-balancing the supply 
and exhaust air.  In rooms with dust extraction installed, the dust extraction air 
volume was also balanced so that the total exhaust air volume could be used to 
calculate the air change rate. 
 
2.6.4 Performance Qualification problems 
The temperature and relative humidity of all the rooms were not always within 
specification.  After careful investigation, a number of causes were identified.  
These were: 
• The fan motor capacities for the air handling units were below 
specification. The design air volumes were obtained but there was not 
room for additional air should the filters block up.  This was remedied by 
replacing all the fan motors for the air handling units with bigger capacity 
motors.  This serious design flaw was noticed by the vigilant HVAC project 
specialist.  If this flaw was not detected in time, the plant would have 
passed the initial qualification with brand new filters.  However once the air 
handling unit filters blocked up, the HVAC systems would not have been 
able to provide the production areas with environmental conditions within 
specification.  It would then have been necessary to take the entire Aspen 
OSD facility down to fix the problem.  Not the ideal situation for a new 
pharmaceutical facility.        
• The heat loading of equipment in the rooms were also under specified and 
therefore the amount of heat generated by the equipment was much 
greater than specified.  The amount of air supplied was therefore not 
enough to take away the heat generated by the equipment when 
operational, thereby increasing the temperature of the air in the room to be 
outside of specification limits.  This problem was remedied by installing 
additional air extraction points in the affected rooms, and removing the hot 
air away at the source before the hot air could influence the room 
temperature condition to be outside of the specification limits. 
• The engineering design for the chilled water system was not adequate for 
the relative humidity control. The cooling tower fan motor which indirectly 
influences the chilled water temperature, was designed with a variable 
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speed drive to slow down or speed up the cooling tower fan speed.  
Fluctuations in the electric current supply caused the cooling tower fan 
motor to trip out from time to time resulting in the chilled water temperature 
increasing, with no fan to reduce it. This problem was remedied by 
removing the variable speed drive and replacing it with a fixed speed drive 
which allowed the fan to rotate at a constant speed. 
• The positioning of the temperature sensors.  The design of the HVAC 
system indicated the positioning of the temperature sensors within the 
overall system.  However, the exact positioning had to be optimised so that 
HVAC control could react quicker to changes.  For example, there was one 
temperature sensor installed in a common duct supplying air to about 10 
rooms.  The duct contained one zone heater.  The temperature sensor was 
connected to the zone heaters, which increased or decreased the air 
temperature accordingly to provide air to the rooms within specification.  
However, if the heat given off by the equipment in one of the rooms was 
higher than the adjacent room, the temperature sensor would take too long 
to detect the change in temperature and thus the zone heaters reaction 
time was too long.  The net results was that the temperature in one room 
would rise above the upper specification limit and fall below the 
specification limit for a long period before the temperature stabilized.  The 
resolution of the HVAC system was therefore not quick enough to respond 
to changes in certain sections of the Aspen OSD facility.  This was the 
same for the relative humidity control.  Both problems were remedied by 
optimising the positioning of the temperature and relative humidity sensors 
so that the responsiveness of the system was quicker, enabling better 
temperature and relative humidity control of the air.  
 
2.6.5 General Issues 
The Aspen OSD management team were under tremendous pressure to get the 
Aspen OSD facility operational.  The facility handover from the contractors was 
planned for January 2004 but the actual date was at the end of March 2005.   
The new “Go Live” date for the Facility was three months later but the overall 
project plan was not changed to take into account this major delay.  The 
manufacture of the first trial batches were as per the original schedule.  The 
building-handover-delay affected the outcome of testing, especially when results 
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did not meet specification. Corrective actions had to be implemented and 
sometimes due to the enormous pressure, further delays were encountered 
such as unavailability of spares, resulting from a not detailed enough spare 
parts list.  This caused testing to be completed over a six to eight month period.  
As mentioned in 2.6.3, the retesting of parameters once corrective actions were 
implemented for the HVAC systems was overlooked and was only highlighted 
during a regulatory audit. 
 
There were not enough validation personnel to perform all the required 
validation/qualifications. During the conceptual phase of the project, consultants 
were involved with the start-up of the project.  The initial prediction of the 
staffing requirement for validation was about fifteen people.  There were only 
two validation officers for the entire project and a third validation officer was 
employed in March 2004, towards the end of the project.  Two assistant 
validation officers were employed in July 2005.  This was remedied by bringing 
validation consultants on board.  However, this solution came with a huge cost 
to the organisation. 
 
Validation officers were not suitably trained in the concepts and principles of 
validation.  The protocols were not written before testing commenced due to the 
lack of resources. The protocols were written and approved whilst 
commissioning was in progress.   
 
If the above factors and the highlighted validation issues are taken into account 
collectively, it can be seen that regardless of the mandatory requirement, implementing 
a Validation programme can save the organisation money.  A study by Wrigley and Du 
Preez [39] stated that, even though the original focus of validation is to satisfy 
regulatory requirements, validation has become a good business, and engineering 
practice, that enhances reliability, cost, and quality of products.  Validation ultimately 
results in bottom line cost savings. 
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CHAPTER 3: CLEANING VALIDATION 
 
 
3.1 Introduction 
 
A study by Cooper [40] states that pharmaceutical, biomedical and even food 
preparation industries are concerned about cleanliness of their products from physical, 
chemical and especially biological contamination.  He mentions that contamination 
comes from the environment, from material in use, the processes, and the people. 
 
The Registrar of Medicine [41] states that cross-contamination should be avoided by 
appropriate technical and organisational measures for example: 
• Producing in segregated areas, or by campaign production followed by 
appropriate cleaning; 
• Providing appropriate air-locks and air extraction; 
• Minimising the risk of contamination caused by re-circulation or re-entry of 
untreated or insufficiently treated air; 
• Keeping protective clothing inside areas where product with special risk of cross-
contamination are processed; 
• Using cleaning and decontamination procedures of known effectiveness; 
• Testing for residues and use of cleaning status labels on equipment; and 
• Controlling microbial contamination by air filtration effective cleaning and 
disinfection.  The area must be neat and tidy at all times to prevent accumulation 
of materials that could promote microbial growth. 
The Registrar of Medicine [42] states that the manufacturing premises should be 
cleaned, and where applicable, disinfected according to detailed written procedures.   
The Registrar of Medicine [43] also states that manufacturing equipment should be 
designed so that it can be easily and thoroughly cleaned according to detailed and 
written procedures and stored only in a clean and dry condition.  The PIC/S Secretariat 
[44] states that cleaning validation should be performed in order to confirm the 
effectiveness of cleaning procedures.   
 
It is clear that pharmaceutical manufacturers must ensure that a cleaning validation 
programme is implemented in their facilities to remain compliant with GMP as defined 
by Regulatory Authorities. 
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3.2 What is Cleaning Validation 
 
The PIC/S Secretariat [45] defines cleaning validation as “documented evidence that 
an approved cleaning procedure will provide equipment which is suitable for 
processing of pharmaceutical products or active pharmaceutical ingredients”.  It states 
that pharmaceutical products can be contaminated by other pharmaceutical products, 
by cleaning agents or by micro-organisms when the same equipment is used for 
processing different products.  To avoid contamination, adequate cleaning procedures 
are essential.   
 
According to LeBlanc [46], cleaning validation must be documented evidence (reports) 
of a high degree of assurance (data evaluations) that cleaning is achieved consistently 
to meet predetermined quality attributes of the equipment repeatedly (doing at least 
three runs). 
 
In summary cleaning validation is nothing more than checking if a system, equipment 
or facility is clean enough to manufacture the next product.  It is the evidence gathered 
to prove that a system, equipment or facility is cleaned to pre-determined levels from 
• Active and inactive ingredients; 
• Cleaning agents and detergents; and 
• Microbial contamination  
 
The Aspen OSD approach was to perform cleaning validation on the three items listed 
above. The levels of residue of the active ingredient were accurately determined.  
Levels of the inactive ingredients and the cleaning agents were determined in a 
combined manner using a technique called “Total Organic Carbons” testing. The 
microbial levels were determined using methods from the United States 
Pharmacopoeia, British Pharmacopoeia, and/or European Pharmacopoeia. 
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3.3 Validation of analytical method for cleaning analysis 
 
The first step before cleaning validation can commence is the validation of the 
analytical methods to determine the levels of contaminants.  The PIC/S Secretariat 
[47] states the following: 
7.10.1 The analytical methods should be validated before the cleaning validation 
study is carried out.   
7.10.2 The analytical method used to detect residuals or contaminants should be 
specific for the substance to be assayed and provide a sensitivity that reflects 
the level of cleanliness determined to be acceptable to the company. 
7.10.3 The analytical method should be challenged in combination with the sampling 
method used, to show that the contaminant can be recovered from the 
equipment surface and to show the level of recovery as well as the 
consistency of recovery.  This is necessary before any conclusions can be 
made based on the sample results.  A negative result may also be the results 
of poor sampling techniques.  
 
The normal procedure for any validation activity is to have a protocol prepared and 
approved prior to commencement of testing.  Thus a protocol defining the extent of 
tests and the acceptance criteria had to be compiled.  Analytical validation is very 
specific and defined in great detail. The parameters for analytical validation of tests 
like assays, dissolution and degradation products are clearly defined in the United 
States Pharmacopoeia, British Pharmacopoeia, and European Pharmacopoeia.  
However, the analytical parameters for cleaning validation methods are more open to 
interpretation.  The standard protocol for validation of analytical methods was revised 
for cleaning validation.  For a template of a cleaning validation protocol refer to 
Appendix 6. 
 
Common techniques for analytical methods for cleaning validation are High-
Performance Liquid Chromatography (HPLC) and Total Organic Carbon (TOC) testing. 
The Aspen OSD approach used the information from the analytical assay seeing that 
this was already validated. The technique and starting conditions for testing the 
amount of enalapril maleate per tablet was used as the starting point for the analytical 
cleaning validation method.   
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The analytical characteristic to be validated was taken from the United States 
Pharmacopoeia [48], Volume 29.  In view of the fact that the testing for levels of 
contaminants is similar to limit tests, the USP Table 2 for quantitative determination was 
used as the prime guide.  The analytical method validation protocol for cleaning 
validation for Enalapril Maleate 10 mg tablets outlines the principles [49]. 
 
3.3.1 Specificity 
Specificity is defined as the ability to assess unequivocally the analyte in the 
presence of components which may be expected to be present and which might 
include impurities degradants, or the sample matrix. [50] 
 
Method 
For the specificity tests, individual and combination solutions were prepared for 
testing.  The following solutions were injected: 
(i) Solvent; 
(ii) Active ingredient (enalapril maleate) at the working concentration; 
(iii) Tablet sample solution at the working concentration; 
(iv) Detergent at the concentration used for cleaning; 
(v) The tablet placebo at the working concentration; and 
(vi) Combination of solutions (ii), (iv), & (v). 
 
The solutions were injected onto an HPLC with a very specific detector, a 
photodiode array detector.  The responses from the detector were in the form of 
peaks with one peak representing one component.  However, a combination of 
responses could give a single peak.  The photodiode array detector checks 
whether the peak responses are “pure” (i.e. that the peak response is due to a 
single component only.  It will detect if the peak response is from a combination 
peak).  A pure peak indicates that the method is specific and is capable of 
detecting the responses of the peaks and components of interest to the study.  
HPLC parameters are changed if the peak is impure in order to separate the 
peaks and ensure that each detected peak is pure.  Refer to Appendix 7 for 
peak purity test chromatograms. 
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Results 
 
Table 2 – Specificity results 
No Solutions Enalapril Response 
Injection 1 
Enalapril Response 
Injection 2 
Mean 
1 Solvent (Acetonitrile) No response No response No response 
2 Working concentration 21193 23988 22590 
3 Tablet at working concentration 21105 21780 21443 
4 Detergent response No response No response No response 
5 Placebo response No response No response No response 
6 Combination 21251 21695 21473 
 
Conclusion 
The method of analysis was able to separate enalapril maleate from the sample 
matrix and impurities.  The method was therefore considered specific for 
enalapril maleate. 
 
3.3.2 Accuracy 
The accuracy of an analytical procedure is defined as the closeness of 
agreement between the value accepted as the true value and the value found 
[50]. 
 
Method   
The Aspen approach was to prepare five solutions at levels of 25%, 50%, 75%, 
100% & 125% the working concentrations.  Each solution was prepared by 
adding a fixed quantity of solute equivalent to make a solution of the required 
concentration.  Five solutions were injected on the HPLC twice and the average 
recovery for each solution was determined. 
 
Procedure for preparing solutions 
1. Enalapril maleate (19.0 mg) of working standard was accurately weighed 
into a 100 mL volumetric flask. 
2. Acetonitrile (20 mL) was added to the volumetric flask, sonicated for 5 
minutes, and diluted to the mark with acetonitrile.  This was the stock 
solution (0.19 mg/mL). 
3. A 25 µL volume of a stock solution was pipetted onto a stainless steel 
plate (ASTM 316L grade), marked with a 5 x 5 cm area. (25% solution) 
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4. The solvent was allowed to evaporate on the plate until a residue was 
visible. 
5. Two pieces of cotton wool of 0.25 and 0.3 g was weighed and wetted 
with 1.5 mL of acetonitrile. 
6. The residue on the stainless steel plate was swabbed by applying four 
horizontal strokes from side to side. 
7. The cotton wool was turned over and the same plate swabbed by 
applying five vertical strokes from top to bottom. 
8. The cotton wool swab was placed in a 150 mL beaker and 20 mL of 
acetonitrile was added to the beaker. 
9. The cotton wool swab was swirled inside the beaker using a glass rod 
and sonicated for 5 minutes. 
10. The glass rod was used to squeeze out most of the solvent and the 
extracted solvent was transferred to a 50 mL volumetric flask. 
11. Acetonitrile 10 mL volume was added and steps 9 & 10 were repeated. 
12. Steps 9 to 11 were repeated using further 10 and 5 mL volumes of 
acetonitrile diluting to the mark with acetonitrile. 
13. 50 µL, 75 µL, 100 µL and 125 µL volumes were used in step 3 above to 
prepare the 50%, 75%, 100% and 125% solutions respectively. 
 
The five solutions was injected using the instrument parameters as specified in 
the method and the amount of enalapril maleate recovered from the swab was 
determined using a solution of enalapril maleate of equal concentration.  The 
acceptance criterion for the accuracy test was recovery of between 98 -102%. 
 
According to Morales Sanchez [51] the swab recovery must be validated to 
determine the amount of analyte recovered from the surface.  He mentions that 
prior to validating equipment cleaning procedures, the various types of 
equipment surfaces must be identified. Thus the accuracy test for the cleaning 
method validation was done using the same surface stainless steel (ASTM 316L) 
as the material of the product contact surfaces. 
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Results 
Table 3 – Accuracy results 
No Solutions Recovery (%) 
1 25 %  98.8% 
2 50 % 100.7% 
3 75% 101.8% 
4 100 % 100.4% 
5 125 %  98.8% 
 
 
Min:  98.8% 
Max: 101.8% 
Mean: 100.1% 
 
Conclusion 
The percentage recovery results meet the acceptance criterion and thus the 
method of analysis was considered accurate. 
 
3.3.3 Method Precision 
Precision of an analytical procedure is defined as the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple 
sampling of the same homogeneous sample under the prescribed conditions 
[52].  
 
Method 
Six different solutions at the working concentration were prepared and analysed 
in duplicate. The sample standard deviation and the relative standard deviation 
of the responses of the six preparations were calculated.  The acceptance 
criterion was that the relative standard deviation be less than 2%. 
 
Results 
Table 4 – Method Precision results 
No Enalapril 
Response 
Results (%) 
1 22963 102.2% 
2 22667 100.9% 
3 22709 101.1% 
4 22377 99.6% 
5 22107 98.4% 
6 22525 100.3% 
 
 
 
Mean: 100.1% 
sd: 1.31 
RSD: 1.31%  
 
Conclusion 
The method precision met the acceptance criterion since the relative standard 
deviation (RSD) was less than 2%.  The method was therefore considered 
precise. 
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3.3.4 Limit of Quantitation 
The quantitation limit of an individual analytical procedure is defined as the 
lowest amount of analyte in a sample which can be quantitatively determined 
with suitable precision and accuracy [52].  There are three approaches for 
determining the limit of quantitation namely [53]:  
• Visual evaluation.  This is used for non-instrumental methods where the 
limit of detection is determined by the analysis of samples with known 
concentrations and establishing the minimum level that the analyte can 
reliably be quantified with acceptable accuracy and precision. 
• Signal-to-noise ratio.  This is used for instrumental methods and 
determined by comparing the signals from samples with known low 
concentrations of analyte with those of the blank samples.  A signal-to-
noise ratio of 10:1 is generally considered acceptable for estimating the 
limit of quantitation. 
• Standard deviation on the response of the slope.  The limit of quantitation 
is expressed as: 
QL = 10 x σ 
  S 
Where  σ = the standard deviation of the response 
 S = the slope of the linear calibration curve 
Method 
The Aspen approach to establish the limit of quantitation was to determine the 
lowest concentration of enalapril maleate at which the relative standard 
deviation (RSD) of six replicate injections must be less than 5.0%. 
Results 
Table 5 – Limit of Quantitation results 
No Enalapril 
Response 
Results (%) 
1 2865 13.97 
2 2944 14.35 
3 2836 13.82 
4 2923 14.25 
5 2950 14.38 
6 2822 13.76 
 
 
 
Mean: 14.08% 
sd: 0.273 
RSD: 1.94 %  
 
Conclusion 
The limit of quantitation for the analytical method was determined to be 14% of 
the working concentration.  This was determined to be 0.053 µg/mL. 
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3.3.5 Linearity 
The linearity of an analytical procedure is defined as the ability to obtain test 
results which are directly proportional to the concentration of analyte in the 
sample [54].  
 
Method 
Five solutions equivalent to 10%, 25%, 50%, 100%, and 150% of the normal 
concentration were prepared.  Each solution was injected into the HPLC and the 
responses for each solution tabulated and a concentration response linear 
graph constructed.  The regressions value R2 was determined from the graph.  
The acceptance criterion for the linearity test was that the coefficient of 
correlation (R2) should exceed 0.99. 
 
Procedure for preparing solutions 
1. Enalapril maleate (19.0 mg) of working standard was accurately weighed 
into a 100 mL volumetric flask. 
2. Acetonitrile (20 mL) was added to the volumetric flask, sonicated for 5 
minutes, and diluted to the mark with acetonitrile.  This was the stock 
solution (0.19 mg/mL). 
3. A 10 µL volume of a stock solution was pipetted into a 50 mL volumetric 
flask and diluted to the mark with acetonitrile. (10% solution). 
4. 25 µL, 50 µL, 100 µL, and 150 µL volumes of stock solution were diluted 
in different 50 ml volumetric flasks to give the 25%, 50%, 100%, and 
150% solutions respectively.  
Results 
Table 6 – Linearity results 
No Solution (%) Enalapril Response 
 
1 10 1456 
2 25 4175 
3 50 10218 
4 100 21048 
5 150 32673 
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Table 7 – Linearity regression statistics 
 
 
 
 
 
Figure 6 – Linearity graph 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
The acceptance criterion for linearity was met since R2 was determined at 
0.9987 which exceeded 0.99.  The response for enalapril maleate was 
concluded to be linear for the concentration range from 10% to 150 % of the 
working concentration. 
 
3.3.6 Range 
The range of an analytical procedure is the interval between the upper and 
lower concentrations of the analyte in the sample for which it has been 
demonstrated that the analytical procedure has a suitable level of precision, 
accuracy and linearity [50]. 
 
Method 
The results as per the limit of quantitation were incorporated into the linearity 
range.   
Regression Statistics 
Multiple R 0.999225618 
R square 0.998451835 
Adjusted R square 0.748451835 
Standard Error 795.3736653 
Observations 5 
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Conclusion 
The range of the analytical method is 25% to 150% of the working concentration 
which is 0,095 µg/mL to 0,57 µg/mL. 
 
3.3.7 System Suitability 
System suitability tests are based on the concept that the equipment, 
electronics, analytical operations, and samples to be analyzed constitute an 
integral system that can be evaluated as such.  The test parameters to be 
established for a particular method depend on the type of method being 
evaluated, especially in the case of a chromatographic method [55]. 
 
Method 
A solution of the working concentration was injected six times on the HPLC.  
The relative standard deviation of the responses of the enalapril maleate peak 
for the six injections was determined for the system precision.  The tailing factor 
and the theoretical plate count (column efficiency) were calculated.  The 
acceptance criteria were as follows: 
(a) The relative standard deviation of the enalapril maleate peak must be 
less than 2% for system precision, 
(b) The tailing factor  (T) must not be more than 2, 
(c) The theoretical plate count (N) of the enalapril maleate peak must be 
more than 1000.   
See Figure 7 and Figure 8 below [55] 
 
Figure 7 – Tailing factor (T) determination 
 
 
Tailing factor is a measure of peak symmetry  
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(T) =  ƒ     
 W0.05 
Where ƒ = the distance as shown in Figure 7 above 
 W0.05 = the peak width at 5% height of the peak as shown in Figure.  
 
Figure 8 – Resolution determination  
 
 
 
Theoretical plate count (N) = 5.54 x (t)2 
      (W h/2)2 
 
Where t = the distance from the start to the peak apex (mm) similar to 
t1 in Figure 8. 
 W h/2 = the peak width at half-height (mm)  
Results 
(a) System Precision 
Table 8 – System Precision results 
No Enalapril 
Response 
1 23278 
2 23221 
3 23238 
4 23252 
5 23658 
6 23253 
 
 
 
Mean: 23316.7 
sd: 168.27 
RSD: 0.72 %  
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(b) Tailing factor 
Table 9 – Tailing factor results 
No Enalapril 
Response 
1 0.88 
2 0.87 
3 0.88 
4 0.89 
5 0.87 
6 0.88 
 
 
 
 
Mean: 0.88 
 
 
(c) Theoretical plate count 
Table 10 – Theoretical plate count results 
No Enalapril 
Response 
1 1369.6 
2 1381.1 
3 1378.0 
4 1392.1 
5 1402.1 
6 1430.0 
 
 
 
 
Mean: 1392.2 
 
 
Conclusion 
The system suitability requirement were all met as the system precision RSD 
was less than 2 %, the tailing factor was less than 2, and the theoretical plate 
count was more than 1000. 
 
3.3.8 The validated analytical cleaning method 
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY 
A. Apparatus and operating conditions 
1. A liquid chromatograph equipped with a high pressure pump and an 
auto-sampler unit. 
2. A variable wavelength UV/VIS detector set at the sensitivity at 0.16 
“Absorbance-Units-Full-Scale” (AUFS) and the wavelength at 215 nm. 
3. An auto-sampler set to inject 50 µl. 
4. An integrator system. 
5. Pump flow rate set at 1.0 mL per minute. 
6. A Luna C-8 column with dimensions (25 cm x 4.6 mm, internal   
diameter) 
7. The column temperature set at 50 ºC. 
8. Mobile phase.  Acetonitrile: Buffer solution.  (25 : 75) 
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Buffer solution 
Dissolve 1.38 g of sodium di-hydrogen phosphate in 800 ml of water.  
Adjust with 85% H3PO4 acid until the pH is 1.2 and dilute to 1000 ml with 
water. 
 
B. Standard preparation 
1. Accurately weigh 19 mg of enalapril maleate into a 100 mL volumetric 
flask (0.19 mg/mL). 
2. Add 20 mL of acetonitrile and sonicate for 5 minutes to dissolve. 
3. Dilute to volume with acetonitrile. 
4. Pipette 100 µL of the above solution into a 50 mL volumetric flask.   
5. Add 20 mL of acetonitrile and dilute to volume with buffer solution. 
6. Filter the standard solution through a 0.45 µm “Millex” filter discarding 
the first 3 mL of filtrate. 
7. Fill an HPLC vial with the standard solution filtrate.  
 
C. Sample preparation 
1. Weigh two pieces of cotton wool weighing 0.25 g and 0.30 g. 
2. Place each cotton wool swab in separate marked beakers. 
3. Wet the 0.3 g swab with 1.5 mL of acetonitrile. 
4. Swab a 25 cm2 surface area of the equipment being tested with the 
wet cotton wool swab, applying four horizontal strokes as shown in 
Figure 9 below.   
 
Figure 9 – Illustration of swab direction 
  
 
 
 
 
5. Rotate the swab and apply four vertical strokes, place the swab back 
into the same beaker and close the beaker to prevent evaporation.   
6. Repeat steps 4 & 5 with the dry 0.25 g cotton wool swab placing the 
swab in the same beaker as in step 5. 
7. Add 20 mL of acetonitrile to the beakers and sonicate for five minutes. 
1 
 
2 
 
3 
 
4 
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8. Swirl the cotton wool pieces inside the beaker using a glass rod and 
squeeze out most of the solvent ensuring that the swab is held to the 
side of the beaker. 
9. Quantitatively transfer the solvent to a 50 mL volumetric flask 
10. Extract the swabs with a further 2 x 10 mL, 1 x 5 mL of acetonitrile 
and dilute to volume with acetonitrile. 
11. Filter the sample solution through a 0.45 µm “Millex” filter discarding 
the first 3 mL of filtrate. 
12. Fill an HPLC vial with the sample solution filtrate. 
 
D. Procedure 
1. Inject 50 µL of the standard solution repeatedly until the retention 
times of the enalapril peak is reproducible 
The peak elutes as follows: 
Compound Retention time 
Enalapril 8.2 minutes 
2. Inject a further 50 µL of standard solution.  The peak areas may not 
differ by more than 2%. 
3. Perform the system suitability test by means of six replicate injections. 
(i) The relative standard deviation of the peak areas of the actives 
for the six replicates is less than 2%. 
(ii) The column efficiency with respect to the enalapril peak is more 
than 1000 theoretical plates. 
(iii) The tailing factor for the enalapril peak is less than 2. 
4. Inject 50 µL of the sample solutions twice and calculate the average 
of the results. 
 
E. Calculation 
mg Enalapril maleate per 25 cm2  = P2 x mass std (mg) x 0.1 mL x 50 mL 
  P1 x 100 mL x 50 mL x 1 mL 
Where 
P1 = area of enalapril peak of the standard solution 
P2 = area of the enalapril peak of the swab sample solution 
mass std (mg) = mass of enalapril maleate taken to prepare the standard 
solution. 
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3.4 Cleaning Validation of Equipment 
 
The Code of Federal Regulations [56] issued by the Food and Drug Administration 
(FDA) states that “Equipment and utensils shall be cleaned, maintained, and sanitised 
at appropriate intervals to prevent malfunction of contamination that would alter the 
safety, identity, strength, quality, or purity of the drug product beyond the official or 
other established requirements” 
 
LeBlanc [57] defines cleaning as “The process of removing contaminants from process 
equipment such that the equipment can be safely used for subsequent product 
manufacture”.  However there are factors that must be considered to effectively clean 
equipment.  Cleaning is dependant on the complexity of the equipment, the nature of 
the surfaces to clean, the material used in the equipment, the method of cleaning, and 
the cleaning process.  All of these factors must be considered before embarking on 
cleaning of equipment.  There are two main types of cleaning namely, “Clean-in-Place” 
(CIP) or “Clean-out-of-Place” (COP).  CIP is usually done using automated cleaning 
processes while the COP involves mainly either semi-automated cleaning process or 
an entirely manual cleaning process (i.e. cleaning is done by people).  There are 
disadvantages and advantages to both.  Inspectors from regulatory authorities prefer 
automated cleaning processes as the capability to consistently clean equipment using 
people is challenging, and requires a great detail to prove effective and efficient 
cleaning.  
 
Within the production environment, there are numerous situations that require different 
levels of cleanliness.  Campaigning is the term used to describe the manufacture of 
multiple consecutive batches of the same product.  During campaigning the cleaning 
regime between batches will be different to the cleaning between different products.  
For campaign batches, the acceptance criterion to check cleanliness will be a visual 
clean (i.e. there are no visible traces of powder present). On the other hand, cleaning 
between different products would require extensive cleaning, sampling (direct or 
indirect), and testing to verify that the results meet the acceptance criteria.  The FDA 
[58] states that it is not necessary to validate the cleaning process between batches of 
the same product.   
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The Aspen OSD approach is in line with the FDA philosophy for campaign batches.  
However, for complex equipment like the Integrated Granulation Suite (IGS) which has 
automated cleaning processes, it is practical to include cleaning rinse cycles between 
batches of the same product.    
  
3.4.1 Establishing Cleaning limits 
A very important question in cleaning validation is “How clean is clean”?  To 
answer that question, limits or acceptance criteria must be established to 
prove that equipment is clean.  If the test results are below the limits, the 
equipment status will be “Clean” and if the test results are above the limits, the 
status would be “Dirty” and re-cleaning will be required.  
 
3.4.1.1 Active residue limit  
According to the Canadian Health Products and Food Branch Inspectorate 
[59] a rationale for selecting limits for product residue must be logical, 
practical, achievable, verifiable, and based on the material involved and their 
therapeutic dose.  The Canadian Health Products and Food Branch 
Inspectorate state that the carry-over product residue must meet the most 
stringent requirement taken from the following criteria: 
i) Not more than 0.1 % of the therapeutic dose of any product in  the 
maximum daily dose of the following product; 
ii) Not more than 10 part per million (ppm) of any product must appear in 
another product; 
iii) No quantity of residue must be visible on the equipment after cleaning 
procedures are completed.  Studies should be undertaken to determine 
the concentration at which most active ingredients are visible. 
iv) Limits have been mentioned of 1/1000 of the normal therapeutic dose. 
 
According to Stahl [60] it is known that the eye can detect about 5 µg/cm2 of 
white substance on a polished stainless steel surface.  Stahl’s approach is 
similar to the Canadian Health Products and Food Branch Inspectorate and 
looks at about four requirements and selects the most stringent requirement to 
act as the cleaning limit. 
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For determining cleaning validation criteria Aspen OSD used a combination of 
approaches [61].  The acceptance limit for a specific product was based on 
the following equations to determine the “Maximum Allowable Carryover” 
(MAC) for the entire equipment train.   
 
MAC1    =    STD x SBS      …………………………………  Equation (a) 
  SF x LWSD      
 
Where: 
MAC = Maximum allowable carryover for the entire surface of the 
equipment train 
STD  = “Smallest Therapeutic Dose” of the active per day 
SBS  = “Smallest Batch Size” of any product made by this equipment 
train at any time (e.g. 292 kg) 
SF  = “Safety Factor” (e.g. 1000) 
LWSD  = “Largest Weight of a Single Dose” of any product made with the 
equipment train at any time. 
 
The MAC is the limit of permitted carryover of residue to the next product.  The 
smallest therapeutic dose (STD) takes into account the potency of the drug 
substance.  If the drug substance is very potent, the smallest therapeutic dose 
would be small making the overall MAC1 value small.  For enalapril maleate 10 
mg tablets, the STD is 2,5 mg.  
 
The smallest batch size (SBS) of product manufacture in the equipment train 
is included in the calculation.  If a contaminant is present in another batch, the 
effect of that contaminant would be the greatest for the smallest batch size. It 
can be seen that the smaller the SBS, the smaller MAC1. For enalapril 
maleate 10 mg tablets the smallest batch size was 292 kg. 
 
The safety factor (SF) is related to 1/1000 of a batch which takes point (iv) of 
the Canadian Health Products and Food Branch Inspectorate criteria into 
account.  The safety factor is included to allow flexibility should the limit of 
quantitation for the active substance be very small.  Toxicologists from the 
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Environmental Protection Agency (EPA) of the United States suggest that 
limits of 1/100 to 1/1000 for toxic material are acceptable [62].  
 
The Largest Weight of a Single Dose (LWSD) is included in the calculation as 
the effect of any contaminant remaining of the previous product will have the 
least effect on the largest dose due to the dilution factor.  Since this value is in 
the denominator of the equation, if the LWSD is big (i.e. a better dilution 
effect), the overall MAC1 is smaller. 
 
MAC = MAC1 x 25    ………………………………….…  Equation (b) 
      SA 
Where 
MAC1   = the value calculated in Equation (a) 
SA  = total Surface Area of the entire equipment train in contact with 
the product 
25 = swab area of 25 cm2 
 
The total surface area (SA) of the equipment train is included in the MAC 
calculation as this indicates the product contact surface area.  If complex 
equipment is used for manufacture of the product the total surface areas will 
be big.  The bigger the total SA, the more swab areas of 25 cm2 will be 
available, and the more swab areas, the lower the MAC.  The surface area of 
the equipment is calculated taking the shape into account.  Where accurate 
measurements cannot be made, estimation that will increase, rather than 
decrease the surface areas is used.  This is done to look at the worst case 
scenario. 
 
All the factors of the MAC calculation look at determining the most stringent 
requirements.  This restricts the allowed levels of contaminants to a minimum.  
For enalapril maleate 10 mg tablets, the MAC was calculated to be 0,019 mg 
per 25 cm2. 
 
MAC1 = 2.5 mg x 292 000 000 mg 
  1000 x 626 mg  
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 = 1166 mg       
Swab areas = 152 0992 cm2 
of 25 cm2       25 cm2 
 
 = 60 840 swab areas of 25 cm2  
 
MAC = 1166 mg 
      60 840 swab areas of 25 cm2 
   
  = 0.019 mg per 25 cm2 
 
3.4.1.2 Microbiological Limits 
The acceptance criterion for microbiological testing is based on limits specified 
in the United States Pharmacopoeia (USP) for purified water.  Similar to the 
active residue limit, swabs are taken and tested according to international 
methodology defined in the (USP).  The microbiological testing is only done on 
swabs and not on rinse samples. 
 
The microbiological limit is defined as the total viable count (bacteria).  It must 
be less than 100 colony forming units per 25 cm2. The limit is identical to the 
microbiological limit for purified water. 
 
If the equipment is not microbiologically clean, it must be sanitized with a 
disinfectant.  The Aspen OSD approach is not to use disinfectants on product 
contact surfaces of equipment.  Sutton [63] states that if disinfectants are 
used, there is a need to rotate the disinfectants as many bacterial organisms 
can develop resistance to specific disinfectants and can therefore survive in 
the presence of the disinfectant.  He recommends rotation of disinfectants to 
prevent development of bacterial resistance.  At Aspen OSD, ethanol (70% 
v/v) is the only disinfectant used on equipment that is in direct contact with the 
product as this is considered pharmaceutically safe.  Apart from rotating 
disinfectants, air quality, people, clothing, and normal hygienic practices can 
influence the levels of microbiological contaminants.    
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At Aspen OSD, in order to restrict the levels of microbiological contaminants, 
the air quality of the production areas are well within the specification limit of 
not more than 100 000 particles of sizes 0.5 µm or less.  In fact the air quality 
is about 100 times better than specification.  Therefore the quality of air is 
good and has little impact on the microbiological bio burden.  The clothing 
worn by personnel in Aspen OSD is of a fibre-free type.  Each production 
employee is provided with five production suites, one for each day of the week 
to reduce the level of potential employee contamination.    
 
The Aspen OSD facility is designed with no ablution rest rooms inside the 
production areas.  Personnel have to move through two airlocks before they 
gain access to the ablution rest rooms. This reduces the potential of 
microbiological contamination of the production environment by the 
employees.   
 
3.4.1.3 Detergent Limits 
The rinse samples are tested for presence of detergents.  The testing is done 
using the total organic carbon (TOC) analyser.  The problem with this type of 
testing is the lack of specificity.  For example if a sample is analysed on the 
TOC Analyzer, all the available carbons in the sample will be detected 
regardless of the origin of the carbon.  For this reason, active residue testing 
cannot be done using only this technique. 
 
The detergent limits for Aspen OSD were determined by looking at all the 
types of detergents to be used and the corresponding concentrations.  At 
Aspen OSD only three detergents are used for cleaning production equipment.  
The recommended dilutions of the three detergents were prepared and 
analysed on the TOC analyzer.  The TOC results were compared to that of 
purified water and limits set on the average TOC results.  The Aspen OSD 
limit for detergent was set at 10 ppm total organic carbon after the 
experimental work was completed. 
 
3.4.2 Types of Sampling 
According to the PIC/S Secretariat [64] there are two methods of sampling 
that are considered acceptable, direct surface sampling (swab method) and 
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indirect sampling (rinse solutions).  Each method of sampling has advantages 
and disadvantages.  A combination of the two methods is generally preferred.   
Direct method 
The direct method is swab sampling.  Advantages of swab sampling are that 
hard-to-clean areas can easily be reached, and that “dried-out” or insoluble 
residues can be physically removed and sampled.  Disadvantages are that 
hard-to-reach places cannot be sampled.  The ability to remove contaminants 
from equipment is dependant on the material of construction of the equipment 
as well as the suitability of the swab material.  Studies must be performed to 
ascertain the suitability of the swab material.  The Aspen OSD approach was 
to perform control swabs with each test.  Fixed amount of the analyte was 
added to the swab and treated exactly the same as a sample.  The amount of 
analyte recovered, indicated the suitability of the swab material. 
 
Indirect Method 
The indirect method is rinse sampling.  A sample of the final rinse water of the 
equipment is collected and tested.  The advantages of rinse sampling are that 
large surface areas as well as inaccessible areas can be sampled. Rinse 
samples can also be tested for the presence of detergents.  Disadvantages 
are that the contaminants may be insoluble in the rinse water. The 
contaminant may be stuck to the equipment and thus difficult to remove by 
rinsing. 
 
Visual Method 
The visual inspection of equipment is sometimes overlooked and cleaning 
validation is clouded by analytical testing.  After cleaning, equipment must be 
visually clean.  If the equipment or facility is not visually clean, re-cleaning 
must take place before any testing commences.  If this mechanism is not 
followed, the cleaning exercise is a waste of time and money.  Resources are 
thus wasted with huge monetary implication, such as production equipment 
standing while waiting for results.  Further delays can be caused whenever 
analytical and microbiological results fail to meet specification.    
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3.5 Problems and associated problem solving 
 
The initial approach to cleaning validation at Aspen OSD was problematic.  There was 
a lack of understanding of cleaning validation by the laboratory analysts and the 
production personnel.  Personnel were not adequately trained to clean the facility.  
Contracted cleaning staff cleaned the production rooms of the OSD Facility whilst the 
operators cleaned the equipment.  There was no ownership for equipment and the 
facility.  For example a production room cannot be used to compress tablets if the 
compression machine as well as the walls, windows, floor and ceiling of the room are 
not clean.  If any component of the manufacturing area is still dirty the process cannot 
proceed. Since the cleaning of the facility was done by a third party company, there 
was a lack of ownership for cleaning.  The responsibility for cleaning the equipment 
was with Aspen employees whilst the cleaning of the facility was the responsibility of 
the contract cleaners.  But the responsibility to manufacture the subsequent product 
rested with the production department.  This created a problem in achieving consistent 
cleaning.  The equipment or the rooms were still visibly dirty which caused result 
failures and unnecessary delays in production. 
 
In summary the cleaning validation problems included the following: 
• Differences in the solubility of the different active ingredients coupled to the use 
of different types of detergents for cleaning specific molecules; 
• Differences in cleaning when equipment or components were cleaned manually 
or automatically; 
• Inconsistency of automated cleaning process to deliver clean equipment due to 
lack of operational understanding of automated cleaning procedures; 
• Production employees not being vigilant when cleaning equipment especially 
complex equipment that required disassembly into different parts; 
• Lack of ownership of the equipment from production personnel; 
• Lack of operator adherence to standard cleaning procedures for equipment; 
• Lack of control of “Clean” equipment versus “Not Clean” equipment; 
• Variations in the levels of cleanliness between operators (i.e. variations within  
operators from the same shift,  from different shifts, different departments, 
different processes) 
• Lack of experience of swabbing  procedure; and 
• Differences in opinion of what is considered visually clean. 
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The majority of the problems were remedied with training and coaching of operators 
and cleaners. Identifying common issues and addressing these issues one-on-one with 
operators from various departments on the various shifts.  The department heads were 
trained on exactly what and where to look when inspecting equipment.  The ownership 
issues were resolved by assigning full responsibility of cleanliness to the process 
operators. Production personnel also implemented pre-inspections prior to informing 
the analytical team to swab the equipment. 
 
Product specific “cleaning recipes” were initiated so that the same detail as the tablet 
manufacturing recipes were described in the cleaning recipes. The cleaning recipes 
contained much more information detailing the how, where and what to clean, and the 
acceptable level required.  The same process as for tablet manufacture was followed 
with the operator signing each step of the cleaning recipe to confirm that the various 
steps were completed. The presence of the operator’s signature acknowledged 
ownership for the cleaning process as well as mechanism to enforce compliance with 
procedures.   
 
A three-fold inspection system was implemented whereby the production team leader, 
the operator as well as the analytical chemist taking the swabs, inspected the 
equipment together.  Whenever visual inspection failures were observed, system 
deviations were initiated, which forced corrective action and preventative actions for 
production personnel.  This elevated the lack of proper cleaning to senior management 
which in turn reduced the cleaning problems. 
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CHAPTER 4:  OPTIMISATION OF ASPECTS OF 
TABLET MANUFACTURE 
 
 
 
4.1 Introduction 
 
The manufacture of tablets for medicinal purposes dates back to 1843 when an 
Englishman named William Brockedon was awarded a patent for a machine that 
compressed powders to form tablets.  The device consisted essentially of a hole (or a 
die) bored through a piece of metal within which the powder was compressed between 
two cylindrical punches; one punch was inserted into the base of the die at a fixed 
depth whilst the other punch was inserted at the top of the die and struck with a 
hammer. This was the first basic invention of tablet manufacture.  The science of tablet 
manufacturing has progressed considerably over the centuries and today tablets are 
the most popular dosage form of medication.  Tablets account for about 70 percent of 
all the ethical pharmaceutical preparations produced [65].   
 
Tablets are solid preparations which contain a single dose of one or more active 
substances.  Tablets are intended for oral administration.  There are those that are 
swallowed whole, others that are chewed, some that are dissolved or dispersed in 
water before being administered, and also those that are retained in the mouth where 
the active substance is liberated. [66] 
 
Some of the essential properties of tablets as a dosage form are that [65]: 
• Tablets must be capable of being swallowed whole, 
• Tablets must provide an accurate dosage of medication, 
• Tablets must contain a known amount of a drug substance(s) or fixed 
combinations of drug substances, 
• Tablets must be stable to air and temperature of the environment over a 
reasonable period of time, 
• Tablets must not be  easily affected by light and moisture, 
• Tablets must be reasonably robust and capable of withstanding normal patient 
handling and transport handling, and 
• The active ingredient(s) in tablets must be available pharmacologically. 
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The majority of tablets are not composed of only the active ingredient. Various 
materials are usually added to make the powder system more compressible.  This is 
done essentially for two reasons viz. powder fluidity and powder compressibility [65].   
 
There are several types of tablets for oral use viz [66]: 
•  Uncoated tablets.  These are tablets that are formed from either single or multiple 
layer compression of particles.  The inactive ingredients used are not intended to 
modify the release of the active substances in the digestive fluids.  
• Coated tablets.  These are uncoated tablets that are covered with one or more 
layers of combinations of various substances such as natural or synthetic resins, 
gums, gelatine, active ingredients, sugars, waxes and sometimes colouring and 
flavouring substances.  The coating substances are usually applied as a solution 
or suspension in conditions in which the coating solvents evaporate.  If the 
coating is very thin, the tablets are known as film-coated tablets. 
• Effervescent tablets.  These are uncoated tablets generally containing acid 
substances and carbonates or hydrogen carbonates which react rapidly in the 
presence of water to release carbon dioxide.  Effervescent tablets are intended to 
be dissolved or dispersed in water before administration. 
• Soluble tablets.  These are uncoated or film-coated tablets that are intended to be 
dissolved in water before administration.  The solutions produced may be slightly 
opalescent due to added inactive ingredients.  
• Dispersible tablets.  These are tablets similar to soluble tablets (uncoated or film-
coated) and intended to be dispersed in water before administration.  Dispersible 
tablets will produce homogeneous dispersions  of solution  
• Orodispersible tablets.  These are uncoated tablets intended to be placed in the 
mouth where they disperse rapidly before being swallowed. 
• Gastro-resistant tablets.  These are also called delayed-release tablets.  They are 
coated tablets and intended to resist the gastric fluids and to release the active 
substance(s) in the intestinal fluids.  These tablets are covered with gastro-
resistant coating and are also called enteric-coated tablets. 
• Modified release tablets.  These are coated or uncoated tablets that contain 
special inactive ingredients or prepared by special procedures.  They are 
designed to modify the rate, place or time of release of the active substance(s).  
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A typical formula of a tablet mixture consists of the following [67]: 
i) Active ingredients.  These substances provide the pharmacological action of the 
medication. 
ii) Binders.  These substances act as adhesives to bind powders together and are 
normally included in the granulating solution. 
iii) Diluents.  These are inert substances which are added in substantial amounts to 
increase the bulk of the powder mixture in order to make reasonable size tablets. 
iv) Disintegrating agents.  These substances promote tablet break-up when placed in 
an aqueous environment.   Disintegrating agents cause tablets to disintegrate 
rapidly by swelling on contact with moisture and bursting the tablet open making 
the active ingredient available to be absorbed. 
v) Glidants.  These substances are added to improve the flow properties of the 
powders by reducing the inter-particulate friction [65]. 
vi) Lubricants.  These substances prevent granules adhering to the surfaces of the 
compression punch faces and dies.  This phenomenon is referred to as “picking”.  
Picking results in the tablet surfaces having a pitted surface instead of smooth 
surface.  Lubricants also assist in the flow properties of powders. 
 
The tablet making process consists of a number of processes which follow in a specific 
sequence.  Tablet making consists mainly of the following processes: 
• Dispensing 
• Granulation  
• Drying 
• Sizing 
• Addition of Glidants and Lubricants 
• Blending  
• Compression  
• Packaging 
 
Dispensing 
Dry powder substances are measured and combined, and placed into specially 
constructed intermediate bulk containers made of stainless steel.  The substances are 
added in predetermined quantities, and in a fixed sequence.  Substances are weighed 
separately using accurate weighing equipment (scales).  The sequence of weighing is 
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according to a fixed formulation or recipe.  In some cases the mixtures of dry powders 
are blended together before proceeding to the granulation phase.   
 
Granulation 
Granulation is the process of increasing the particle size of powdered ingredients in 
order to confer powder fluidity and powder compressibility to the powder system.  The 
granulation process converts dry powders into agglomerates and then into granules.  
The ideal properties of a good granule are [65]:  
1. That once compacted physical strength and form is conferred to the tablets; 
2. That all the ingredients are uniformly distributed throughout the granule mix; 
3. That the particle size distribution of the granules is statistically normal (i.e. there 
should be small percentages of both fine and coarse particles); 
4. That the granule shape is as close as possible to the spherical shape; 
5. That the granule is robust enough to withstand handling without breaking; and 
6. That the granule is relatively dust free thus minimizing powder spread during the 
tablet-making stage. 
 
The granulation process can either be wet granulation or dry granulation.  Wet 
granulation is most widely used and consists of a granulating solution in which the 
binders are normally incorporated.  Powders are moistened using sufficient granulating 
agent to render the powder coherent so that it will “ball” in the hand but is not too 
damp.  The coherent mass or agglomerate is then passed though a suitable sieve prior 
to the drying phase.     
 
Drying 
Granule can be dried by either fluidised bed drying or static bed drying.  In fluidised 
bed drying, the sifted mass is dried by passing warm air upwards through the granule 
thereby “fluidising’ the mass whilst drying.  Static bed drying is the process by which 
the sifted mass is spread on trays in thin layers, and exposed to large volumes of 
warm air at specified temperatures to dry the sifted mass to pre-determined moisture 
levels.  
   
Sizing 
During drying the granule forms agglomerates.  Hence the dried granule is sized to a 
preset particle size.  This step is called “Sizing”.  Sizing is controlled by specifying the 
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sieve sizes through which dried granule must be passed to achieve a specific particle 
size distribution. 
 
Addition of Glidants and Lubricants 
Glidants and lubricants are added after the sizing phase to improve the flow properties 
of the granule. Glidants reduce the inter-particulate friction and assist with the blending 
or mixing of granule.  The glidants and lubricants are added in “layers” prior to the 
blending phase to allow improved mixing and better distribution of active and inactive 
ingredients.  
 
Blending 
During this phase, all the ingredients of the formulation or recipe have been combined 
in a single container.  The granules are mixed together in a specialised blender at 
specified speed and for a specified period of time to afford a homogenous mixture of 
granule.  The critical parameters for the blending phase are the mixing time and the 
mixing speed.  If the granular powders are mixed too slowly for short periods of time, 
the granular mixture will not be homogeneous. Similarly, if the granules are mixed too 
fast and for prolonged periods of time, then “de-mixing” of the ingredients can occur. 
De-mixing occurs when the active and inactive ingredient particles segregate from the 
total blend giving rise to non-homogeneity of the blended granule.  De-mixing can also 
destroy the integrity of the granule which will cause poor granule flowability, capping 
and marking of tablets, and failures of the physical attributes of the tablets.  De-mixing 
may also give rise to tablets with poor dissolution properties. 
 
Compression 
This is the actual tablet-making stage or “Compression” stage.  The granule is 
compacted to form tablets.  The blended granule is placed into an intermediate bulk 
container (IBC), on the first floor of the production facility.  The compression machine 
is situated on the ground floor directly underneath the IBC.  The granule flows by 
gravitational force from the IBC through an opening in the floor to the compression 
machine.  Powder flowability is a main factor in compression and is the chief 
contributor to the physical and chemical properties of the tablets produced. 
 
Compression machines are normally rotary tablet machines and consist of a circular 
rotating head which contain three basic parts viz: upper part which carries the upper 
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punches, the central part or turret which carries the dies, and the lower part which 
carries the lower punches.  The basic mechanism of tablet compression is as follows;     
the hopper delivers the granular powder to the feed frame placed over the turret 
containing the dies.  The turret rotates and each die in the turret moves under the feed 
frame in succession, and is filled with granule [68].  Tablet compression takes place 
when the upper and lower punches pass between the upper and lower rollers.  This 
causes the punches to penetrate the dies to a pre-set depth.  The granular powder in 
each die is compacted to the thickness of the gap setting between the punch surfaces 
and by this means produces tablets of equivalent thickness. 
 
Figure 10 –  Cross sectional diagram of the punch tracks of rotary tablet 
machine [68]  
F – Feed frame with granules, U. – Upper punches, U.R. – Upper Roller 
 
 
 
L – Lower Punches, W – Capacity adjuster, L.R – Lower Roller,  
 
Figure 10 shows the cycle of events.  The upper punch is lifted and the lower punch is 
raised to “pop” the tablet out of the die.  The compressed tablets are directed via a 
tablet chute and collected in suitably labelled containers.  The bulk tablets are kept 
secured until the packaging process commences.   
 
The shape of the tablets and the embossing on the tablets is engraved according to 
the shape and writing on the tablet punches.  For example to compress a biconvex 
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tablet, embossed “Lennon” on the one side, the upper and lower punches will both be 
concave in shape with the mirror image of the wording “Lennon” engraved on the one 
punch. 
 
Packaging 
Packaging is the process in which tablets are enclosed in different types of containers 
to provide the patient and/or customer with the final product. The Registrar of Medicine 
[69] states that particular attention must be given to minimising the risk of cross-
contamination, mix-ups or substitutions when setting up a programme for the 
packaging operation.  Good manufacturing practices (GMP) are essential, especially 
for the packaging process since mistakes can easily occur during packaging with 
catastrophic effects.  For instance, if labels are accidentally placed on the wrong 
containers, or if  tablets are placed in wrong packaging, the wrong treatment will be 
administered to patients.  This may seriously jeopardize the health of the patients.  
Therefore strategic quality systems are put in place to perform multiple checks to 
reduce the risks of packaging errors. 
 
Tablet packaging may be in various forms.  The choice of packaging is normally 
selected by the marketing branch of the business.  However the choice of packaging 
for a particular product is also dependant on the packaging that provides the best shelf 
life for the product.  At Aspen Pharmacare, products are typically packed in the 
following types of packaging: 
• Blister packaging.  Bubble strips containing one tablet in each bubble. 
• Securitainer packaging.  Plastic bottles with plastic lids which indicate if the 
bottles have been opened. 
• Patient ready packs.  Sealed bank bags, pre-labelled with instructions.  Each 
bag containing the correct number of tablets for specific treatments (e.g. tablets 
for a week or a month).   This packaging is preferred by Hospitals and Clinics. 
• Polyvinyl chloride (PVC) bottles.  Plastic bottles with special seals containing 
child-tamper-proof lids. 
Enalapril maleate 10 mg tablets are packed in blister packaging.  The blister strips 
consist of aluminium foil as the base as well as aluminium foil blisters.  This type of 
packaging is commonly known as foil-on-foil blister packaging. 
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4.2 Enalapril maleate 10 mg tablet process flow 
 
Figure 11 – Enalapril maleate 10 mg tablet process flow [70] 
 
 Ingredients    Phases   Equipment  
 
Enalapril maleate 
Lactose, Starch maize,  
Dye P/B Red PB25094          
Î 
 
Dispensing Í
 
Intermediate Bulk Container 
     
Starch maize (dried) Î  Í Lubricant Bins 
Zinc stearate     
  Ð   
Enalapril maleate, 
Lactose, Starch maize,  
Dye P/B Red PB25094 
Î 
 
Mixing Í
Glatt Vertical Granulator 
VG 800 
  Ð   
Granulating medium: 
Starch paste 
 
Î 
Granulation  
Í
Glatt Vertical Granulator 
VG 800  
  Ð   
  Drying 
 Í
Glatt FBD WSG PRO 200 
   Ð   
Starch maize (dried) 
Zinc stearate Î 
Sizing  
 Í
GS 180 Mill 
  Ð   
  Blending Í SP 2000 Single Pedestal Blender 
  Ð   
  Compression 
 Í
Compression Machine 
  Ð   
  Blistering 
 Í
TR135 Blister Machine 
  Ð   
  Autocartoning operation 
 Í
A73 Autocartoning Machine 
 
 
Figure 11 illustrates the various phases of the tablet manufacturing process for 
enalapril maleate 10 mg tablets.  From Figure 11 the ingredients can be explained as 
follows: 
• Lactose is the diluent, 
• Enalapril maleate is the active ingredient,  
• Dye is an inactive ingredient used for giving the tablets a specific colour, 
• Starch maize is used as a binder to make starch paste, 
• Starch maize and zinc stearate are the glidant and lubricant respectively. 
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4.3 Blending optimisation 
 
The blending phase is a critical phase of a tablet manufacturing process. The main 
objective of the blending operation is to ensure that a homogeneous mix of the active 
ingredient(s) and inactive ingredients (excipients) is achieved. Correct blending 
ensures that there is no high concentration or low concentration of any of the individual 
components of the mix. Failure to achieve a homogeneous mix will result in non-
uniform distribution of the active ingredient of individual tablets [70]. 
 
There are a few critical parameters that have been identified which can affect the 
blending phase and ensure homogeneity of the mix.  These are: 
• The size of the container that holds the granular mixture.  Aspen OSD has four 
sizes of intermediate bulk containers (IBCs) viz; 150, 800, 1600 & 1900 litres.   
• The percentage loading of the container used for blending. Generally only about 
70 percent of the container must be filled otherwise there is not sufficient 
headspace in the container to afford good mixing.  The sizes of the containers for 
blending are specified per product for a specific batch size. 
• The mode of blending or the type of blender equipment.  Aspen OSD has only 
one blender, the SP 2000 Blender.  The IBCs fit exactly into the blender and 
therefore the type of equipment and mode of blending is constant.    
• The speed of rotation.  The blender efficacy is dependent on the speed of 
operation.  If the operation is too slow, it will not produce the desired intense 
tumbling or cascading motion, nor will it generate rapid shear rates.  Rotation that 
is too rapid tends to produce centrifugal forces sufficient to hold the powder to the 
sides of the mixer and hence reduce mixing efficiency [71].   The supplier 
recommended speed for the sizes of IBCs for the SP 2000 Blender was 10 
revolutions per minute (rpm), thus the speed of rotation was fixed at 10 rpm. 
• The blending times.  This parameter was experimentally optimised.  
• The size of the samples.  If the sample size is too big, a sample of a sample is 
tested.  If the sample is too small, it will not be enough to perform the analytical 
testing.  Aspen OSD has standard sampling equipment that withdraws ± 1.5 g of 
sample.  The sample quantity is similar to keep this variable constant.  
• The points at which samples are taken.  This is kept relatively constant with the 
use of a pictorial representation of sampling points.  Refer to Figure 12. 
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Figure 12 – Sampling point inside an intermediate bulk container [71] 
 
 
 
 
4.3.1 Procedure for blending time optimisation 
 Experiments were conducted to demonstrate that the SP 2000 blender was 
capable of producing a uniformly blended granule for enalapril maleate 10 mg 
tablets for the batch size of 3 600 000 tablets.  The homogeneity of the blending 
process was checked by determining the mass per mass percentage of active 
content (enalapril maleate) as well as one of the inactive ingredients (zinc 
stearate).  Samples were taken from nine (9) sampling points inside the 800 litre 
intermediate bulk container (IBC) as illustrated in Figure 12. The sampling 
points were labelled as follows: 
i) 5 x top segment (centre, north, south, east, west);  
ii) 3 x middle segment (centre, east, west); 
iii) 1 x bottom segment (centre).  
 
Samples were taken after blending for 10, 15, and 20 minutes to establish the 
optimum blending time.  The testing was done on three batches, A700001, 
A700008 & A700009 of product.  The testing procedures were as follows: 
a) Enalapril maleate.  The analysis was done as per Aspen OSD method of 
analysis, item number 375790. 
b) Zinc stearate. The analysis was done using the validated atomic 
absorption spectrophotometric method.      
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4.3.2 Results of blending time optimisation [72] 
a) % mass per mass enalapril maleate.   
 
 
Table 11 – Batch A700001, 10 minute blending 
 
 
Table 12 – Batch A700001, 15 minute blending 
 
 
Table 13 – Batch A700001, 20 minute blending 
 
 
% m/m enalapril maleate  
Batch: A700001 Blending time: 10 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 9.70 9.86 9.81 9.84 9.86 9.81 0.07 0.68 
Middle Segment 9.66   9.86 9.76 9.76 0.10 1.02 
Bottom Segment 9.67        
Mean 9.68     9.78   
SD 0.02      0.08  
% RSD 0.22       0.86 
% m/m enalapril maleate  
Batch: A700001 Blending time: 15 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 10.23 9.33 9.67 10.08 9.73 9.81 0.36 3.67 
Middle Segment 9.93   10.04 9.70 9.89 0.17 1.75 
Bottom Segment 9.95        
Mean 10.04     9.85   
SD 0.17      0.271  
% RSD 1.67       2.76 
% m/m enalapril maleate  
Batch: A700001 Blending time: 20 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 9.69 10.06 9.76 9.64 9.60 9.75 0.18 1.88 
Middle Segment 9.91   9.91 9.86 9.89 0.03 0.29 
Bottom Segment 9.76        
Mean 9.79     9.80   
SD 0.09      0.15  
% RSD 0.94       1.51 
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Table 14 – Batch A700008, 10 minute blending 
 
 
Table 15 – Batch A700008, 15 minute blending 
 
 
 
Table 16 – Batch A700008, 20 minute blending 
 
% m/m enalapril maleate  
Batch: A700008 Blending time: 10 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 9.92 10.32 10.31 10.19 9.69 10.09 0.27 2.72 
Middle Segment 10.21   9.96 9.76 9.96 0.23 2.31 
Bottom Segment 9.71        
Mean 9.95     10.01   
SD 0.25      0.26  
% RSD 2.52       2.56 
% m/m enalapril maleate  
Batch: A700008 Blending time: 15 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 9.84 9.89 9.94 10.38 10.10 10.03 0.27 2.72 
Middle Segment 9.95   10.38 9.88 10.07 0.23 2.31 
Bottom Segment 10.03        
Mean 9.94     10.04   
SD 0.10      0.21  
% RSD 0.96       2.06 
% m/m enalapril maleate  
Batch: A700008 Blending time: 20 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 10.02 10.00 9.92 10.09 10.01 10.01 0.06 0.61 
Middle Segment 9.97   9.89 10.02 9.96 0.07 0.66 
Bottom Segment 9.82        
Mean 9.94     9.97   
SD 0.08      0.08  
% RSD 0.86       0.82 
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Table 17 – Batch A700009, 10 minute blending 
 
 
 
Table 18 – Batch A700009, 15 minute blending 
 
 
 
Table 19 – Batch A700009, 20 minute blending 
 
 
% m/m enalapril maleate  
Batch: A700009 Blending time: 10 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 9.93 9.62 9.87 9.80 9.68 9.78 0.13 1.32 
Middle Segment 9.76   9.50 9.76 9.67 0.15 1.55 
Bottom Segment 9.52        
Mean 9.74     9.72   
SD 0.21      0.15  
% RSD 2.12       1.53 
% m/m enalapril maleate  
Batch: A700009 Blending time: 15 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 9.76 9.78 9.59 9.70 10.16 9.80 0.22 2.20 
Middle Segment 9.86   9.95 10.25 10.02 0.20 2.04 
Bottom Segment 10.24        
Mean 9.95     9.92   
SD 0.25      0.24  
% RSD 2.54       2.46 
% m/m enalapril maleate  
Batch: A700009 Blending time: 20 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 9.75 9.64 9.65 10.01 9.87 9.78 0.16 1.60 
Middle Segment 10.05   10.43 10.00 10.16 0.24 2.31 
Bottom Segment 10.30        
Mean 10.03     9.97   
SD 0.22      0.27  
% RSD 2.24       2.75 
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4.2 Results of blending time optimization (continued) 
 
b) % mass per mass zinc stearate 
 
Table 20 – Batch A700001, 10 minute blending 
 
 
 
Table 21 – Batch A700001, 15 minute blending 
 
 
Table 22 – Batch A700001, 20 minute blending 
 
 
% m/m zinc stearate  
Batch: A700001 Blending time: 10 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 0.160 0.160 0.156 0.162 0.160 0.160 0.002 1.37 
Middle Segment 0.156   0.157 0.160 0.158 0.002 1.32 
Bottom Segment 0.165        
Mean 0.160     0.160   
SD 0.005      0.003  
% RSD 2.81       1.83 
% m/m zinc stearate 
Batch: A700001 Blending time: 15 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 0.166 0.161 0.168 0.162 0.164 0.160 0.003 1.74 
Middle Segment 0.162   0.166 0.160 0.163 0.003 1.88 
Bottom Segment 0.169        
Mean 0.166     0.164   
SD 0.004      0.003  
% RSD 2.12       1.94 
% m/m zinc stearate 
Batch: A700001 Blending time: 20 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 0.171 0.169 0.164 0.168 0.168 0.168 0.003 1.52 
Middle Segment 0.178   0.172 0.169 0.173 0.003 2.65 
Bottom Segment 0.165        
Mean 0.171     0.169   
SD 0.01      0.004  
% RSD 3.80       2.43 
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Table 23 – Batch A700008, 10 minute blending 
 
 
 
Table 24 – Batch A700008, 15 minute blending 
 
 
 
Table 25 – Batch A700008, 20 minute blending 
 
 
% m/m zinc stearate  
Batch: A700008 Blending time: 10 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 0.167 0.164 0.169 0.162 0.169 0.166 0.002 1.87 
Middle Segment 0.176   0.162 0.168 0.169 0.01 4.16 
Bottom Segment 0.175        
Mean 0.173     0.168   
SD 0.005      0.01  
% RSD 2.86       3.01 
% m/m zinc stearate 
Batch: A700008 Blending time: 15 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 0.166 0.159 0.164 0.136 0.161 0.157 0.01 7.73 
Middle Segment 0.165   0.162 0.157 0.161 0.004 2.51 
Bottom Segment 0.164        
Mean 0.165     0.159   
SD 0.001      0.01  
% RSD 0.61       5.79 
% m/m zinc stearate 
Batch: A700008 Blending time: 20 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 0.169 0.168 0.178 0.169 0.182 0.173 0.01 3.68 
Middle Segment 0.170   0.170 0.171 0.170 0.001 0.34 
Bottom Segment 0.151        
Mean 0.163     0.170   
SD 0.01      0.01  
% RSD 5.35       5.00 
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Table 26 – Batch A700009, 10 minute blending 
 
Table 27 – Batch A700009, 15 minute blending 
 
Table 28 – Batch A700009, 20 minute blending 
 
4.3.3 Acceptance criteria 
The acceptance criteria for the percentage mass per mass results were as 
follows: 
a) % m/m of enalapril maleate must be within the range 9.50 to 10.50 % 
b) % m/m of zinc stearate must be within the range 0.132 to 0.178 %. 
% m/m zinc stearate  
Batch: A700009 Blending time: 10 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 0.158 0.168 0.156 0.167 0.168 0.163 0.01 3.61 
Middle Segment 0.161   0.174 0.163 0.166 0.01 4.22 
Bottom Segment 0.164        
Mean 0.161     0.164   
SD 0.003      0.01  
% RSD 1.86       3.40 
% m/m zinc stearate 
Batch: A700009 Blending time: 15 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 0.166 0.162 0.167 0.155 0.157 0.161 0.01 3.30 
Middle Segment 0.161   0.154 0.167 0.161 0.01 4.05 
Bottom Segment 0.168        
Mean 0.165     0.162   
SD 0.004      0.01  
% RSD 2.19       3.39 
% m/m zinc stearate 
Batch: A700009 Blending time: 20 minutes 
Sample Centre North South East West Mean SD % RSD 
Top Segment 0.164 0.162 0.165 0.167 0.169 0.165 0.003 1.63 
Middle Segment 0.162   0.163 0.176 0.167 0.01 4.68 
Bottom Segment 0.172        
Mean 0.166     0.167   
SD 0.01      0.005  
% RSD 3.19       2.91 
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4.3.4 Discussion 
a) % m/m of enalapril maleate 
The blending time data was statistically evaluated using the Kruskal-Wallis [73] 
and Levene test [74].  The Kruskal-Wallis is a non-parametric method that tests 
the equality of population means in three or more independent groups of data.  
The Levene test verifies that the variances within groups are equal. It differs 
from the analysis of variance (ANOVA) as ANOVA assumes that the variances 
are equal whereas the Levene test verifies that assumption.  Hypothesis testing 
is used in which a null hypothesis (H0) is defined.  Usually the null hypothesis 
states that the population means or that the variation of the data is not 
significantly different and the alternative hypothesis (Ha) will state that the 
population means or the variation is significantly different.  This would be 
defined symbolically as follows: 
Null hypothesis  H0:  x1 = x2 = x3   
Alternative hypothesis  Ha:  x1 ≠ x2 ≠x3   
 
The probability that the null hypothesis is accepted or rejected is calculated.  
This is referred to as the p-value of the test. Low p-values indicate that the null 
hypothesis is unlikely to be correct and should be rejected. Traditionally, p-
values below 0.05 are taken to be sufficient evidence that the null hypothesis be 
rejected.  For example, if the p-value for two data sets is 0.96, the probability 
that the null hypothesis must be accepted is 96% and the probability that null 
hypothesis must be rejected is 4%.  On the other hand, a p-value of 0.001 
indicates that there is a 0.1% chance that the null hypothesis must be accepted 
and a 99.9 % chance that the null hypothesis must be rejected. 
 
The results from batches A700001, A700008 & A700009 were tested according 
to the Kruskal-Wallis and Levene tests.  The results from the following samples 
were evaluated: 
i) Top segments samples 
ii) Middle segment samples 
Since only one sample was taken at the bottom of the intermediate bulk 
container for each batch at each time, there was insufficient data to statistically 
evaluate the bottom results. 
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b) % m/m results of zinc stearate 
The zinc stearate results were assessed based on the relative standard 
deviation of the results. 
Table 29 – Comparison of variation of blending times for zinc stearate 
 A700001 A700008 A700009 
 
10 
minutes 
15 
minutes 
20 
minutes 
10 
minutes 
15 
minutes 
20 
minutes 
10 
minutes 
15 
minutes 
20 
minutes 
n 9 9 9 9 9 9 9 9 9 
min 0.16 0.16 0.16 0.16 0.14 0.15 0.16 0.15 0.16 
max 0.17 0.17 0.18 0.18 0.17 0.18 0.17 0.17 0.18 
mean 0.16 0.16 0.17 0.17 0.16 0.17 0.16 0.16 0.17 
sd 0.003 0.003 0.004 0.005 0.009 0.008 0.006 0.005 0.005 
RSD 1.83 1.94 2.24 3.01 5.79 5.00 3.40 3.39 2.91 
 
Table 29 showed that all the results for the three blending times, for the three 
batches all met the acceptance criteria.  The lowest relative standard deviation 
(RSD) was evident for the 10 minute blending time for batches A700001 and 
A700008.  However the 20 minute blending time had the lowest RSD for batch 
A700009. Statistical evaluations were not performed on the zinc stearate results 
as the homogeneity of the active content and not the inactive was important for 
the product. 
 
4.3.5 Summary of statistics  
 i) Top segment samples 
Table 30 – Kruskal-Wallis/Levene results for Top segment results 
 n=5 Batches Mean SD 
Blending Time 10 min A700001 9.81 0.067 
  A700008 10.09 0.274 
    A700009 9.78 0.129 
Test Means Kruskal-Wallis p = 0.141   
Test Variances Levene Test p =   0.008 
     
 n=5  Mean SD 
Blending Time 15 min A700001 9.81 0.356 
  A700008 10.03 0.219 
    A700009 9.8 0.215 
Test Means Kruskal-Wallis p = 0.239   
Test Variances Levene Test p =   0.335 
     
 n=5  Mean SD 
Blending Time 20 min A700001 9.75 0.183 
  A700008 10.01 0.061 
    A700009 9.78 0.157 
Test Means Kruskal-Wallis p = 0.069   
Test Variances Levene Test p =   0.187 
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Table 30 showed that the p-values for the Kruskal-Wallis analysis for the top 
segment blending times of 10, 15 & 20 minutes were 0.141, 0.239 & 0.069 
respectively.  This provided sufficient evidence that the null hypothesis could not 
be rejected.  Statistically there was no significant difference between the mean 
values of the enalapril maleate content for the blended samples at 10, 15 & 20 
minutes for the top segments.   
 
The Levene tests showed p-values of 0.008, 0.335 & 0.187 for the 10, 15 and 
20 minute blending times respectively.  Again there was sufficient evidence not 
to reject the null hypothesis for the 15 and 20 minutes samples which illustrated 
that the variation of the 15 & 20 minutes samples were homogeneous.  
However, the low p-value obtained for the 10 minutes sample indicated a 
significant difference in the variation of the three batches at 10 minutes. 
 
ii) Middle segment samples 
 
Table 31 – Kruskal-Wallis/Levene results for Middle segment results 
 n=3 Batches Mean SD 
Blending Time 10 min A700001 9.760 0.100 
  A700008 9.977 0.225 
    A700009 9.673 0.150 
Test Means Kruskal-Wallis p = 0.221   
Test Variances Levene Test p =   0.464000 
     
 n=3  Mean SD 
Blending Time 15 min A700001 9.890 0.173 
  A700008 10.070 0.271 
    A700009 10.020 0.204 
Test Means Kruskal-Wallis p = 0.750   
Test Variances Levene Test p =   0.538 
     
 n=3  Mean SD 
Blending Time 20 min A700001 9.893 0.029 
  A700008 9.960 0.066 
    A700009 10.160 0.235 
Test Means Kruskal-Wallis p = 0.079   
Test Variances Levene Test p =   0.018745 
 
Table 31 showed that the p-values for the Kruskal-Wallis analysis for the middle 
segment blending times of 10, 15 & 20 minutes were 0.221, 0.750 & 0.079 
respectively.  Similarly there was sufficient statistical evidence that no significant 
difference existed between the mean results for the three blending times.    
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The Levene tests showed p-values of 0.464, 0.538 & 0.0187 for the 10, 15 and 
20 minute blending times respectively.  Again there was statistical evidence that 
the variation within the batches was homogeneous for the middle segment 
samples taken at 10, 15 & 20 minute blending times.     
 
A proposed equation for the two variables, location and time was formulated 
from the data using linear regression.  The proposed equation is as follows: 
 
Ŷ = b0 + b1 Location + b2 Time + b3 Location x Time 
 
The p-values were calculated using linear regression for the coefficients b0, b1, 
b2 & b3 to ascertain if they differ significantly from zero.  If the coefficients were 
zero, the entire term would be zero which would prove that the variable has no 
impact on the outcome of the active content of enalapril maleate. 
 
Table 32 – Proposed model coefficients tests 
      
  b Std.Err. t(68) p-level 
Intercept b0 9.942 0.121 81.968 0.000 
Location b1 -0.310 0.198 -1.565 0.122 
Time b2 -0.005 0.008 -0.590 0.557 
Location x Time b3 0.025 0.013 1.939 0.057 
   
 
Table 32 showed a low p-value for b0 which meant that b0 was not zero. P-
values for b1, b2 & b3 greater than 0.05 indicated statistically evidence that these 
coefficients were zero.  This meant that sample location inside the intermediate 
bulk container, and the blending time did not influence the mass per mass 
percentage of enalapril maleate.  However, the p-value for b3 was 0.057 which 
was very close to 0.05.  Statistically there was less evidence that the coefficient 
b3 was not zero which meant that the interaction between sample location inside 
the tank, and the blending time was significant.  This would influence the 
percentage mass per mass of enalapril maleate significantly.   
 
It should be noted that the blender used in the General Facility, called a 
“Turbula” Blender has a different mode of tumbling to that of the SP2000 
Blender. The Turbula Blender has a push-pull tumbling action while the SP2000 
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Blender has a rotational action of a large funnel-shaped intermediate bulk 
container.  All the products blended in the Turbula Blender are blended for 10 
minutes at 16 rpm.  With the history of the blending speeds in the Turbula 
Blender that works for a very large range of products it was decided to blend the 
products in the SP 2000 blender for longer at a slower rotational speed.  
 
It is important to note that the integrity of the granule cannot be destroyed 
during blending as this will lead to granule flowability problems and tablet 
compression problems. Longer blending times may cause de-mixing which will 
lead to physical tablet appearance problems, flowability problems, and 
dissolution problems.  Over-blended granule leads to high rejection rates and 
eventually the batch must be destroyed or reworked. There is a reluctance to 
conduct experiments with long blending times due to the high cost implication 
and potential production problems. 
 
Perusal of the data showed no statistical significance of sample location and 
blending time.  However, realistically and practically, longer blending times will 
destroy the integrity of the granule which will lead to product problems and high 
rejection rates.  The blending time for the manufacture of enalapril maleate 10 
mg tablet, batch size of 3 600 000 tablets, was set at 15 minutes. 
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4.4 Tablet compression optimisation 
 
Tablet compression follows the blending phase of the manufacturing process.  During 
tablet compression actual tablets are formed through compaction of the blended 
granule. Simply stated, the mass of blended granule is converted to smaller units 
called tablets.  The tablets should be uniform in appearance, physical dimensions, and 
should contain the correct amount of active ingredient. For this reason critical 
parameters of this phase must be optimised as well.   
 
The success of tablet compression depends on whether the blended granule is 
homogenously mixed; whether the blended granule has good flow properties, and 
whether the tablet compression parameters have been optimised.  A critical variable in 
tablet compression is tablet uniformity (i.e. the variation from one tablet to the next 
must be minimized otherwise the tablets will vary in mass, thickness and physical 
appearance).  The parameters that influence tablet uniformity are: 
• Depth of the die filling.  This is determined by measuring the tablet mass.  If the 
mass is too low, the compressed tablets will be thin and soft, and the active 
content per tablet will be below specification.  Patients will receive an under-
dose of the active ingredient.  If the mass is too high, the compressed tablets 
will be thick and hard, and the active content per tablet will be above 
specification.  High active content per tablet will lead to patients receiving an 
overdose of the active ingredient.  It is therefore important to optimise this 
parameter. 
• Degree of pressure applied by the pressure roller.  This is determined by 
measuring the tablet hardness.  If the pressure is too high, the tablet will be very 
hard and thin.  If the pressure is too low, the tablet will be soft and breakable 
and not intact after packaging.  Hence patients will receive broken tablets.  This 
is another parameter that must be optimized. 
• Speed of rotation of the tablet compression machine.  Faster compression 
speeds will deliver more tablets per minute but the quality of the tablet may be 
compromised.  Slower compression speeds will cause a batch to take longer to 
complete resulting in longer production times.  It is important to find the optimum 
speed that satisfies both quality and production, i.e. good quality tablets that can 
be produced in the minimum amount of time. 
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The variables that could influence the speed of rotation of the tablet compression 
machine are: 
a) Tablet average mass.  This is a measure of the tablet mass. 
b) Tablet friability. This is a measure of the tablet softness, and whether is will 
withstand transport and handling. High friability results indicate soft, poor quality 
tablets. 
c) Tablet hardness.  This is a measure of the tablets hardness. Harder tablets will 
be less friable than softer tablets.  Thus harder tablets will have lower friability. 
d) Tablet thickness.  This is a measure of the physical tablet thickness.  Tablet 
thickness is interrelated with hardness.  Harder tablets will be thin in dimension 
and softer tablets will be thicker in dimension.  Tablet thickness also influences 
the packaging operation, especially if blister packaging is specified.  Variation in 
tablet thickness will make blister packaging difficult causing an increase in 
packaging rejects. 
e) Physical attributes of tablets. This is an evaluation of the physical appearance of 
the compressed tablets. The tablets are inspected for signs of capping, binding 
or marking.  Tablets with poor physical attributes will be discarded. 
 
Experimental testing was used to decide the optimum speed of operation for the 
compression machine. Even though acceptance criteria for each of the above 
parameters were pre-determined during product development, it was necessary to 
optimise the interactions of these parameters in order to obtain good quality tablets at 
a competitive production rate.   
 
4.4.1 Procedure for compression speed optimisation 
Three batches of enalapril maleate 10 mg tablets A700015, A700017 & 
A700018 were compressed at different speeds on the Courtoy rotary tablet 
compression machine.  The three batches were compressed at speeds of 2250, 
3250, 4250 & 5000 tablets per minute (tpm) and samples taken from each 
speed were tested.  The results are tabulated in Tables 36, 37, 38, 39 and 40. 
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4.4.2 Results of compression speed optimisation [75] 
a) Tablet average mass  
Table 33 – Results of tablet average mass  
No Batch 2250 tpm 3250 tpm 4250 tpm 5000 tpm 
1 A700015 100.8 mg 98.0 mg 99.5 mg 100.0 mg 
2 A700017 101.2 mg 100.7 mg 100.0 mg 99.7 mg 
3 A700018 101.2 mg 99.4 mg 100.2 mg 99.6 mg 
Confidence Intervals 
95 % Lower limit 100.5 mg 96.0 mg 99.0 mg 99.2 mg 
95 % Upper limit 101.6 mg 102.7 mg 100.8 mg 100.3 mg 
Acceptance Limit:  96.5 to 103.5 mg.  Target mass 100.0 mg 
 
b) Tablet friability 
Table 34 – Results of tablet friability  
No Batch 2250 tpm 3250 tpm 4250 tpm 5000 tpm 
1 A700015 0.19 % 0.21 % 0.17 % 0.04 % 
2 A700017 0.11 % 0.14 % 0.08 % 0.09 % 
3 A700018 0.11 % 0.10 % 0.23 % 0.06 % 
Confidence Intervals 
95 % Lower limit 0.02 % 0.01 % -0.03 % 0.00 % 
95 % Upper limit 0.25 % 0.29 % 0.35 % 0.13 % 
Acceptance Limit:  Not more than 1.0 % 
 
c) Tablet hardness  
Table 35 – Results of tablet hardness  
No Batch 2250 tpm 3250 tpm 4250 tpm 5000 tpm 
1 A700015 33 N 28 N 31 N 36 N 
2 A700017 36 N 32 N 32 N 35 N 
3 A700018 37 N 33 N 34 N 36 N 
Confidence Intervals 
95 % Lower limit 30.2 N 24.4 N 28.5 N 34.2 N 
95 % Upper limit 40.5 N 37.6 N 36.1 N 37.1 N 
Acceptance Limit:  20 to 55 N 
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4.4.2  Results of compression speed optimization (continued) 
d) Tablet thickness 
Table 36 – Results of tablet thickness  
No Batch 2250 tpm 3250 tpm 4250 tpm 5000 tpm 
1 A700015 2.31 mm 2.28 mm 2.29 mm 2.27 mm 
2 A700017 2.30 mm 2.30 mm 2.30 mm 2.25 mm 
3 A700018 2.32 mm 2.28 mm 2.30 mm 2.26 mm 
Confidence Intervals 
95 % Lower limit 2.29 mm 2.26 mm 2.28 mm 2.24 mm 
95 % Upper limit 2.33 mm 2.32 mm 2.31 mm 2.28 mm 
Acceptance Limit:  2.07 to 2.53 mm   
 
e) Physical attributes of the tablets 
Table 37 – Results of physical attributes of tablets  
No Batch 2250, 3250, 4250 & 5000 tpm 
1 A700015 No capping, binding or marking 
2 A700017 No capping, binding or marking 
3 A700018 No capping, binding or marking 
Acceptance limit:  No capping, binding or marking 
 
4.4.3 Acceptance Criteria 
The acceptance limits for tablet hardness, average mass, friability, tablet mass 
and physical attributes were preset as follows: 
a) Tablet average mass.  96.5 to 103.5 mg, with a target value of 100.0 mg. 
b) Tablet Friability.  Not more than 1% mass per mass lost. 
c) Tablet hardness.  20 to 55 Newton (N). 
d) Tablet thickness.  2.07 to 2.53 mm, with a target value of 2.30 mm. 
e) Physical attributes of tablets.  No capping, binding or marking. 
 
4.4.4 Discussion 
a) Table 33 showed that the average mass results that were the closest to 
the target mass for batch three batches were measured at 5000 tpm for 
batch A700015 and at 4250 tpm for batches A700017 & A700018.  The 
95% confidence intervals for all four speeds showed that the true 
population mean for average mass fell within the acceptance limits. 
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b) Table 34 showed that the lowest friability results were obtained at a 
compression speed of 5000 tpm with the exception of batch A700017.  
Batch A700017 gave the lowest friability at compression speed of 4250 
tpm.  The 95% confidence interval showed that the true population mean 
for tablet friability fell within the acceptance criteria for all four speeds. 
 
c) Table 35 showed that the highest hardness results for the three batches 
were measured at the 2250 and 5000 tpm.  This was the slowest and 
fastest operation speeds for the compression machine.  Similarly, the 
95% confidence intervals showed that the true population mean for tablet 
hardness fell within the acceptance criteria for all four speeds. 
 
d) Table 36 showed that the thickness results closest to the target value for 
the four compression speeds were obtained at 4250 tpm for all three 
batches. Again the 95% confidence intervals showed that the true 
population mean for tablet thickness fell within the acceptance criteria for 
all four speeds. 
 
e) Table 37 showed that the physical attributes of the compressed tablets at 
each of the compression speeds did not show signs of capping, binding 
or marking.  The physical characteristics of the final tablets were not 
affected by the compression speeds.  
 
Statistically the speed of compression did not affect tablet average mass, tablet 
friability, tablet hardness and tablet thickness.  The combined results of the five 
parameters, the statistical evaluation as well as the rate of production were 
considered to decide the optimum compression speed.  Taking these factors 
into account, the compression speed for enalapril maleate 10 mg tablets for 
batch size 3 600 000 tablet was set at 5000 tpm. 
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4.5 Process Validation  
 
Process validation batches are batches of product that are manufactured once the 
manufacturing parameters have been optimised to prove that the manufacturing 
process can consistently deliver product meeting predetermined specifications and 
attributes.  According to the Registrar of Medicine [76], process validation batches may 
be sold if the conditions under which the batches were produced fully comply with the 
requirements of current Good Manufacturing Practices (cGMP).  It is generally 
accepted that three consecutive batches/runs within the agreed parameters, would 
constitute evidence of validation of the process.  Three batches of enalapril maleate 10 
mg tablets viz, A700015, A700017 and A700018 were manufactured as the validation 
batches.  Each unit process in the manufacturing step was individually validated as 
part of a continuous process.  Samples were taken at the different stages of the 
manufacturing process as defined in the Process Validation Protocol [70].  Refer to 
Appendix 8.  The document control for process validation protocols is similar to that for 
the design qualification, installation qualification, operational qualification, performance 
qualification, and cleaning validation protocols.  Process validation protocols must be 
compiled, reviewed and approved by authorised personnel. 
 
The manufacturing procedures for enalapril maleate 10 mg tablets with a batch size of  
3 600 000 tablets are specified in a document called the batch manufacturing record 
(BMR).  The BMR is the product recipe and provides the exact operating conditions 
and parameter settings for each stage of the manufacturing process.  Thus the 
optimum blending time (15 minutes) as well as the optimum compressions speed 
(5000 tpm) is defined in the BMR.  Similarly the optimum settings for the granulation 
parameters and the optimum conditions for the other stages of manufacturing process 
are defined in the BMR.  However, the optimisation of these parameters is not 
discussed in this paper.   
 
4.5.1 Procedure for process validation 
Samples were taken as per process validation protocol for batches A700015, 
A700017 & A700018.  The samples included: 
a) Dry powder mix in the granulation bowl.  During the dry powder mixing 
prior to granulation, samples were taken from the top, middle, and bottom 
of the mixer after mixing the dry powders. 
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b) Bulk and tap density of the blended granule.  Final blended granule 
samples were taken to determine the bulk and tap density.  The bulk 
density was determined by placing 100 gram of granule into a measuring 
cylinder and measuring the volume it occupies.  The bulk density is 
determined by dividing the mass by the volume.   
 
The tap density is determined by placing the same measuring cylinder in 
a device that taps the granule in an up-down motion to compact the 
granule. The granule is tapped 2500 times and the volume re-measured. 
The tap density is then determined by dividing the mass by the volume.  
The “tapped volume” is always lower than the bulk volume as the 
compacted powder occupies less space and hence the tap density 
values are always bigger than the bulk density values.   
 
The Hausner ratio [77] is calculated from the tap and bulk density results.  
The Hausner ratio is an indication of the flowability of the granules.  
Granules with a Hausner ratio of 1.2 or less indicate granules that have 
good flow properties whilst granule with a Hausner ratio of 1.6 or greater, 
indicate poor flow properties.  The Hausner ratio is calculated as follows:   
 
Hausner ratio = tap density/bulk density 
 
c) Loss on drying.  The moisture content of the granule will influence the 
physical characteristics of the final tablet.  The moisture content is 
determined using the loss on drying method in which a granule sample is 
taken after drying and the moisture determined.  Each product has fixed 
loss on drying test acceptance limits.  Loss on drying results within the 
accepted limits is an in-process step which gives confidence to proceed 
to the following stage in the tablet manufacturing process. 
d) Blend uniformity (nine point sampling). The homogeneity of the active 
content throughout the blended granule is verified by withdrawing 
multiple samples as described in 4.3 above and determining the 
percentage mass per mass of enalapril maleate, the active content. 
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e) Compressed tablets testing. Analytical tests and limits are defined for 
each product in the various international pharmacopoeias. The 
pharmacopoeial monographs clearly specify the analytical procedure and 
equipment for the testing.  The analytical test results indicate the quality 
of the compressed tablets. Tablet properties can be measured by 
selecting an appropriate subset of analytical testing from the 
pharmacopoeial monograph for the product.  The selected tests must be 
based on three main criteria viz; the physical appearance of the tablet, a 
measure of uniformity of the active per tablet, and a measure of the rate 
of the active dissolution once taken by a patient. Therefore the specific 
tests selected were: 
• Tablet hardness.  A measure of the hardness of the tablets which 
directly affects the rate of dissolution.  Harder tablets tend to have 
longer dissolution times. 
• Average tablet mass.  A measure of the average mass of the 
tablets.  This parameter is directly linked to the uniformity of active 
content.  If the average mass is not adequately controlled the active 
content per tablet will differ. 
• Uniformity of content.  A measure of the percentage of enalapril 
maleate per tablet, and the amount of active a patient will receive 
after a tablet has been administered.  Ten individual tablets are 
separately analysed for the active content per tablet. 
• Dissolution. A measure of the percentage of enalapril maleate 
dissolved within thirty (30) minutes.  The rate at which the active 
content is available to be absorbed into the blood stream after a 
tablet has been administered.  Six tablets are placed into separate 
dissolution vessels inside a dissolution apparatus and operated for 
30 minutes.  After the time has elapsed, aliquots from each 
dissolution vessel is withdrawn and analysed to determine the active 
content dissolved. 
 
Samples of compressed tablets taken at the start, middle and end of 
batches A700015, A700017 & A700019 were tests as described above.  
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4.5.2 Results for process validation [75] 
a) Dry powder mix results 
Table 38 – Dry powder mix results (% m/m enalapril maleate)  
No Batches Top Middle Bottom mean sd RSD 
1 A700015 11.54 % 11.85 % 11.29 % 11.56 % 0.28 2.43 % 
2 A700017 11.15 % 11.28 % 11.12 % 11.18 % 0.09 0.76 % 
3 A700018 11.71 % 11.79 % 11.55 % 11.68 % 0.12 1.05 % 
Limits for dry powder mix:  10.98 to 12.14 % m/m 
 
b) b) Bulk and tap density results 
Table 39 – Bulk & tap density results   
Parameters A7000015 A700017 A7000018 
Bulk density  0.78 g/ml 0.74 g/ml 0.72 g/ml 
Tap density  0.96 g/ml 0.93 g/ml 0.90 g/ml 
Hausner ratio 1.23 1.26 1.25 
Limit for Hausner ratio:  Not less than 1.2 
 
c) Loss on drying results 
Table 40 – Loss on drying results   
Batches A7000015 A700017 A7000018 
Loss on Drying (LOD) 1.57 % 1.59 % 1.43 % 
Limits for LOD: 1.0 to 1.6 %  
 
d) Blended granule results 
Table 41 – Batch A700015, % m/m enalapril maleate results  
 
 
 
 
 
 
 
 
 
Batch: A700015 
Sample Centre North South East West Mean SD % 
RSD 
Top Segment 9.70% 9.57% 9.68% 9.57% 9.68% 9.64% 0.06 0.67 
Middle Segment 9.74%   9.61% 9.72% 9.69% 0.07 0.72 
Bottom Segment 9.63%        
Mean 9.69%     9.66%   
SD 0.05      0.06  
% RSD 0.47       0.65 
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Table 42 – Batch A700017, % m/m enalapril maleate results 
 
 
 
 
 
 
 
 
 
Table 43 – Batch A700018, % m/m enalapril maleate results 
 
 
 
 
 
 
 
 
 
e) Compressed tablet results 
Table 44 – Batch A700015 results 
Batch A700015 
No Tests Start Middle End Limits 
1 Tablet hardness (N) 31.6 N 33.8 N 30.2 N  20 to 55 N 
2 Average mass (mg) 101.7 mg 101.0 mg 99.53 mg 96.5 to 103.5 mg 
3 
Uniformity of Content (%) 
Min: 
 
  97.0 % 
 
103.4 % 
 
 95.0 % 
 
85 to 115 % of  
 Max: 113.7 % 111.4 % 107.6 % enalapril maleate per 
 Mean: 103.9 % 107.3 % 102.8 % tablet 
 RSD:     5.2 %     2.5 %     4.1 % Not more than 6.0 % 
4 
Dissolution (%) 
Min: 
 
  94.0 % 
 
  98.2 % 
 
  96.9 % 
 
Not less than 85 % of  
 Max: 100.9 % 104.6 % 102.9 % enalapril maleate is 
 Mean   97.5 %  101.6 %   99.4 % released within 30 
minutes 
Batch: A700017 
Sample Centre North South East West Mean SD % 
RSD 
Top Segment 9.78% 9.64% 9.62% 9.53% 9.64% 9.64% 0.09 0.93 
Middle Segment 9.55%   9.75% 9.70% 9.67% 0.10 1.08 
Bottom Segment 9.74%        
Mean 9.69%     9.66%   
SD 0.10      0.09  
% RSD 1.04       0.91 
Batch: A700018 
Sample Centre North South East West Mean SD % 
RSD 
Top Segment 9.86% 9.65% 9.77% 9.77% 9.86% 9.78% 0.09 0.88 
Middle Segment 9.94%   9.84% 9.86% 9.88% 0.05 0.54 
Bottom Segment 9.80%        
Mean 9.87%     9.82%   
SD 0.06      0.08  
% RSD 0.58       0.84 
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Table 45 – Batch A700017 results 
Batch A700017 
No Tests Start Middle End Limits 
1 Tablet hardness (N) 26.8 N 26.0 N 30.2 N  20 to 55 N 
2 Average mass (mg) 100.4 mg 100.9 mg 100.9 mg 96.5 to 103.5 mg 
3 
Uniformity of Content (%) 
Min: 
 
  95.8 % 
 
  99.0 % 
 
102.4 % 
 
85 to 115 % of  
 Max: 107.3 % 107.8 % 108.5 % enalapril maleate per 
 Mean: 103.2 % 103.3 % 104.6 % tablet 
 RSD:     3.0 %     2.5 %     1.7 % Not more than 6.0 % 
4 
Dissolution (%) 
Min: 
 
  97.5 % 
 
  95.3 % 
 
  96.7 % 
 
Not less than 85 % of  
 Max: 100.5 %   97.1 % 103.6 % enalapril maleate is 
 Mean   98.9 %    95.8 % 100.3 % 
released within 30 
minutes 
 
Table 46 – Batch A700018 results 
Batch A700018 
No Tests Start Middle End Limits 
1 Tablet hardness (N) 25.8 N 31.4 N 31.6 N  20 to 55 N 
2 Average mass (mg) 99.1 mg 100.2 mg 100.0 mg 96.5 to 103.5 mg 
3 
Uniformity of Content (%) 
Min: 
 
  96.7 % 
 
100.3 % 
 
  94.7 % 
 
85 to 115 % of  
 Max: 108.9 % 113.6 % 114.9 % enalapril maleate per 
 Mean: 101.5 % 107.3 %   99.5 % tablet 
 RSD:     4.5 %     3.5 %     6.0 % Not more than 6.0 % 
4 
Dissolution (%) 
Min: 
 
  97.5 % 
 
  96.3 % 
 
  93.9 % 
 
Not less than 85 % of  
 Max: 100.5 %  101.1 % 102.8 % enalapril maleate is 
 Mean   98.9 %    98.2 %   98.3 % 
released within 30 
minutes 
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4.5.3 Acceptance criteria 
The acceptance limits for dry powder mix, bulk and tap density, loss on drying, 
blend uniformity and compressed tablet testing were preset as follows: 
a) Dry powder mix. 10.98 to 12.14 % m/m of enalapril maleate. 
b) Bulk and tap density. Not more than 1.2. 
c) Loss on drying.  1.0 to 1.6 % moisture 
d) Compressed tablets testing.   
1 Hardness.  20 to 55 N 
2 Average mass.  96.5 to 103.5 mg 
3 Uniformity of content.  85 to 115 % m/m of enalapril maleate per 
tablet. 
4 Dissolution.  Not less than 85 % of enalapril maleate is dissolved 
within 30 minutes. 
 
4.5.4 Discussion 
a) Table 38 showed that the % m/m enalapril for the dry powder mixture for 
all three batches were within specification.  However, the relative 
standard deviation of batch A700017 was the smallest indicating the 
least variance of the active content in the mix.  
 
b) Table 39 showed that the bulk and tap density results were very similar 
for the three batches ranging from 0.72 to 0.78 g/ml.  The Hausner ratios 
for the three batches were all close to 1.2 which indicated that the three 
batches showed satisfactory flow properties. 
 
c) Table 40 showed that all the moisture for the three batches were within 
specification.  Batch A700017 gave the highest moisture result that was 
very close to the upper limit.  It must be noted that all three batches 
showed excellent compression characteristics with no signs of binding, 
capping or marking which indicated that the moisture content of the 
granule was not too high.  
 
d) Tables 41, 42 & 43 showed that the blended granules gave homogenous 
distribution of the active content with the nine point results for the three 
batches all within specification.  The maximum results were obtained in 
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the middle segment for batches A700015 (middle centre – 9.74 %) and 
A700018 (middle centre – 9.94 %).  Batch A700017 gave the maximum 
result at the top segment (top centre – 9.78 %)  
 
e) Tables 44, 45 & 46 showed that the tablet hardness, average mass, 
uniformity of content and well as the dissolution results for the three 
batches were within specification.  If the process is followed, the granules 
at the bottom of the intermediate bulk container (IBC) will be compressed 
first and constitute the tablets at the start of the batch.  The middle 
tablets will be compressed from the middle segment granules, and the 
end tablets will be compressed from granule situated at the top of the 
container.  Interestingly it was noted that for batches A700015 and 
A700018 the maximum blended results were reported for the middle 
segments.  The mean results for the uniformity of content as well as the 
dissolution test of the compressed tablets for these two batches were 
reported for the middle samples.  This matched the blended granule 
results.  Similarly batch A700017 showed maximum blended granule 
results at the top segment.  Again the maximum mean result for the 
uniformity of content as well as the dissolution was reported for the end 
sample of this batch.  The blended granule results were also matched.  
The fact that the maximum results for the blended granule matched the 
maximum results for the uniformity of content, it was decided to perform 
statistical evaluations on the uniformity of content results to assess 
whether significant differences existed between the mean results for the 
three batches (A700015, A700018 & A700019) at the three positions 
(start, middle & end).  The two variables were batch and position. 
 
Table 47 – ANOVA results for uniformity of content 
 df SS MS F p-value 
Intercept 1 968134.9 968134.9 60245.92 0.000000 
Batch 2 56.1 28.1 1.75 0.180962 
Position 2 235.5 117.7 7.33 0.001190 
Batch*Position 4 220.5 55.1 3.43 0.012148 
Error 81 1301.6 16.1   
Total 89 1813.7       
 
Table 47 showed p-values of 0.001 and 0.012 for position and the 
interaction between batch and position respectively.  There was sufficient 
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evidence to justify that statistically, a significant difference existed 
between the mean results of the three batches for samples taken at the 
different positions.  The p-value for the main effect of batch (i.e. the 
difference between batches) was greater than 0.05 which suggested that 
no significant difference existed in the mean results for the three batches.  
However, the effect of different batches cannot be interpreted in isolation 
because interaction exists between batch and position.  In summary, 
samples taken from the three positions, start middle and end were 
different for the three batches.  This difference is statistically significant 
and cannot be overlooked.   
 
A proposed equation model was formulated using step wise regression.  
Step wise regression arrives at the best fitting model by eliminating 
insignificant variable. The following model equation was proposed: 
 
Ŷ = b0 + b1Batch + b2 Position + b3 Batch x Position 
 
The p-values were calculated for the coefficients b0, b1, b2 & b3 to 
ascertain if they differ significantly from zero.  If there was sufficient 
statistical evidence that the coefficients are zero, the entire term would 
be excluded from the proposed equation and the variable would have no 
effect on the results for enalapril maleate content per tablet. 
 
Table 48 – Proposed model coefficients tests (uniformity of content) 
       
  Std.Err. B Std.Err. t(86) p-level 
Intercept b0  101.9345 0.643186 158.4837 0.000000
Batch b1 0.116985 1.9485 1.114031 1.7491 0.083850
Position b2 0.116985 5.3955 1.114031 4.8432 0.000006
Batch x Position b3 0.135082 -5.9965 1.929558 -3.1077 0.002556
 
Table 48 showed that b0, b1 & b2 gave p-values much lower than 0.05 
which suggested evidence that the coefficients are not zero.  Statistically 
this meant that the average enalapril maleate content per tablet was 
significantly different in the middle position than at the start and the end 
position. This supported the statistical conclusions reached from the 
results in Table 47. The mean results were calculated using the 
proposed model equation. 
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Table 49 – Proposed uniformity of content results from the model 
 Position 
Batch Start Middle End 
A700015 101.93 % 107.33 % 101.93 % 
A700017 103.88 % 103.28 % 103.88 % 
A700018 101.93 % 107.33 % 101.93 % 
 
Table 49 showed that the proposed mean results for batches A700015 
and A700018 were not any different at the start and end.  However, the 
proposed mean results for the middle position for all three batches 
increased.  This increase was proven to be statistically significant.  It 
must be noted that the proposed model eliminates experimental error 
and is different from the actual mean results obtained.  Uniformity of 
content sample is taken at random and as such the sample will include 
tablets taken from the middle segment of the batch. This increases the 
chance that the random sample represents the entire batch.  
 
Perusal of the results of the samples taken illustrated that three batches of the 
enalapril maleate 10 mg tablets manufactured using the optimised parameters 
and using equipment that has been qualified, will produce product that 
consistently meet specification.  The process for the manufacture of enalapril 
maleate 10 mg, batch size 3 600 000 tablets is declared validated. 
 
4.6 Conclusion 
 
The science of tablet manufacture has developed from the early days when the top 
punch was manually struck with a hammer to produce one tablet to the latest 
sophisticated, fully-automated compression machines that produce 5000 tablets per 
minute. Manufacturing processes require optimisation and tablet manufacture is no 
exception.  In order to produce quality products at competitive prices, aspects that 
influence the outcomes of the manufacturing processes must be studied and 
optimized.  This study has shown that it is beneficial to dedicate time and effort to 
optimize the various processes and sub-processes to achieve the goal of making 
products that consistently meet predetermined quality standards and specifications. 
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CHAPTER 5:  BUSINESS MODEL 
 
 
5.1 Introduction 
 
The most important objective of business is to generate profits.  Non-profitable 
businesses will simply be declared bankrupt and employees will subsequently lose 
their jobs.  Hence the main objective of any organisation’s executive team is to provide 
business strategies that will achieve maximum profitability and sustained growth. With 
profitability and growth come benefits such as high return on investment, increasing 
share prices, job stability, improved market position, new jobs, lower unemployment, 
socio-economic investments, and competing in markets of choice to name a few. Thus 
businesses are constantly looking for ways to improve objectives.  This is done by 
introducing new visions and strategies. Validation, even though a regulatory 
requirement, can be seen as a business strategy that can contribute significantly 
towards achieving maximum profitability and sustained growth. 
 
The intention of this business model is to illustrate that validation reduces 
manufacturing costs by reducing rejects and reworks.  A cost analysis will be done by 
comparing the manufacturing costs of enalapril maleate 10 mg tablets in the new 
Aspen OSD facility which has a structured validation programme to that of making the 
same product in an older General facility without a structured validation programme.  
The comparative study will focus chiefly on the cost associated with non-conformances 
for each facility.  The number of batches of enalapril maleate 10 mg tablets 
manufactured over a period of one year in both facilities will be compared.   
 
The cost comparison will evaluate the cost of non-conformances for the manufacture 
of enalapril maleate 10 mg tablets at both the Aspen OSD facility (new) and the 
General facility (old).  Factors like batch size, product range and number of employees 
will be taken into account and where necessary, factors will be normalised to provide 
an unbiased comparison.  
 
Before the cost of non-conformances can be determined, the cost of quality must be 
calculated.  Lillrank [78] states that prevention and appraisal costs are unavoidable but 
that internal and external failure costs are bad avoidable costs that can be reduced.   
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Figure 13 – Cost of poor Quality [78] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Figure 13 Lillrank summarises the cost of poor quality and clearly identifies four 
categories to determine the cost of quality.  He states that the cost of quality is 
assigned to things not being done right the first time.  He also states that the cost of 
quality is a “counter-intuitive term” and that the term “cost of non-conformance” or “cost 
of poor quality” (COPQ) should be used.   
 
Juran and Gryna [79] groups quality costs into the same four categories as Lillrank.  
Their explanation of quality costs does not differ considerably from Lillrank and defines 
quality costs as follows: 
5.1.1 Internal failure costs.    
Internal failure costs would disappear if no defective products were 
manufactured.  Internal failure costs include: 
• Rejects/Scrap.  The net loss in labour and materials used to manufacture 
the defective products which cannot be economically re-used or recovered. 
• Reworks.  The cost of correcting defects to make them fit for use. 
• Retests.  The costs of re-inspection and retesting of products which have 
been reworked. 
     - 106 -
• Down time.  The cost of idle facilities resulting from the defect products.  
The downstream equipment in the process that is idle while defective 
products are manufactured upstream.   
• Yield losses.  The cost of process yields lower than the standard yields that 
might have been attained by improved controls (e.g. variability in 
measuring equipment causing “overfills” of products going to customers). 
 
5.1.2 External failure costs 
External failure costs would also disappear if no defective products were 
manufactured.  However, these costs are different from internal failure costs as 
the defective products are detected after the customer has received the product.  
External failure costs include: 
• Complaint adjustments.  The costs associated with the investigation of 
customer complaints, and the costs of adjustment to products that may 
have the same problem as the complaint once the complaint has been 
justified. 
• Returned material.  The costs associated with the receipt and replacement 
costs of the defective products returned from the market.  Costs associated 
with repairs and warranty claims. 
• Allowances.  Cost associated with concessions made to customers due to 
substandard products being accepted by the customer.  It includes loss of 
income due to downgrading products for sale as “seconds”.   
 
5.1.3 Appraisal costs 
These are the costs incurred to discover the condition of the product, also 
known as the cost of detecting defects.  Appraisal costs include: 
• Incoming material inspection.  The costs of determining the quality of 
vendor made products whether by inspection on receipt, or inspection at 
source. 
• Inspection and test.  The costs of checking the conformance of the product 
throughout the progression in the factory.  It includes all material tests, 
packing and shipping tests, final acceptance tests, shelf life and 
environmental tests.  The costs include costs for outside services engaged 
for the purposes of testing. 
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• Maintaining accuracy of test equipment.  The costs of operating and 
keeping measuring instruments and equipment within calibration. 
• Materials and services consumed.  The costs of the products consumed 
with destructive testing. 
• Evaluation of stock.  The costs of testing products in storage to determine 
shelf life and degradation.    
 
5.1.4 Prevention costs 
These costs are incurred to keep failure and appraisal costs to a minimum.  
Prevention costs include: 
• Quality planning.  This includes a broad selection of activities which 
collectively create the overall quality plans (e.g. inspection plans, testing 
plans, data systems and specialised plans).  It includes the preparation 
and control of manuals, work instructions, and procedures. 
• Training.  The costs of preparing training programmes for attaining and 
improving quality performance. 
• New-product review. The costs associated with future proposals, 
evaluation of new designs, preparations of test and experimental 
programs, and quality activities related to launching new products or new 
processes. 
• Improvement projects.  The costs of structured programmes to promote 
breakthroughs to new levels of performance (e.g. defect prevention 
programmes and motivational programmes).  
 
5.2 Cost of non-conformance model 
 
A model for calculating the cost of non-conformances for enalapril maleate 10 mg 
tablets will be created.  The model will be used to calculate the non-conforming cost of 
both sites.  The following information will be tabulated in the model for General facility 
and Aspen OSD: 
 
5.2.1 Internal Failures 
a) Total number of batches manufacture during the last twelve month period. 
b) The number of batches rejected or scrapped. 
c) The associated cost of rejected or scrapped batches. 
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d) The number of batches retested to confirm rejects. 
e) The associated cost of retesting. 
f) The number of batches reworked. 
g) The associated cost of reworks. 
h) The batch size in terms of number of tablets. 
i) The theoretical number of tablets manufactured. 
j) The average yield of bulk tablets manufactured. 
k) The actual yields of each batch versus the standard yield for this product. 
l) The number of tablets rejected due to yield losses. 
m) Cost of yield losses which include bulk and packaging yield losses 
n) Total cost of internal failures. 
 
5.2.2 External Failures 
a) The number of complaints received and the associated costs involved in 
the responses 
b) Product replaced. 
c) The associated cost of replacing product. 
d) Returned product costs 
e) Total external failures. 
 
5.2.3 Appraisal and Prevention costs  
These costs are fixed whether defective products are produced or not. The 
actual costs of making enalapril maleate 10 mg tablets at the General facility 
and Aspen OSD facility will be indicative of the appraisal and prevention costs. 
 
 
5.3 Cost comparison of Aspen OSD versus General Facility 
 
Due to the confidentiality of the information, the actual figures were remodelled to 
protect the sensitivity of the information.  However for the purposes of comparison the 
same remodelling was done for both facilities and the final cost differences were 
expressed in percentage.  The costs of non-conformance model are tabulated below 
under Aspen OSD Facility and Aspen General Facility. 
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Table 50 – Non conformance cost comparison 
 Activities  Aspen OSD Aspen GF 
5.3.1 Internal failure costs 
a) Number of batches manufactured  5 13 
b) Number of batches rejected 0 0 
c) Cost of number of batches rejected R 0.00 R 0.00 
d) Number of batches retested 0 3 
e) Cost of number of batches retested  R 0.00 R 21 000.00 
f) Number of batches reworked 0 2 
g) Cost of number of batches reworked R  0.00 R 116 924.00 
h) Batch size (number of tablets) 3 600 000 1 800 000 
i) Total number of tablets manufactured 25 200 000  23 400 000 
j) Average yields of batches manufactured 94.71 % 92.23 % 
k) Total bulk tablet yield versus standard 0.29 % loss 2.77 % loss 
l) Number of tablets rejected due to yield loss 1 333 080 1 818 180 
m) Cost of yield losses (bulk + pack)  R 162 500.97 R 221 634.12 
n) Total cost of Internal failure R 162 500.97 R 359 558.12 
5.3.2 External failure costs 
a) Number of complaints received. 0 5 
b) Product replaced 0 packs 30 packs 
c) Cost associated with complaint responses R  0.00  R 410.10 
d) Returned product costs R  0.00  R   0.00 
e) Total cost of External failure R  0.00 R 410.10  
5.3.3 Appraisal and Prevention costs 
 Cost per batch R   32 846.40 R   14 095.38 
 Total Appraisal and Prevention costs 
(Cost per batch x number of batches) 
R 164 232.00 R 183 239.94 
Total cost of Non-Conformance 
1 Total cost of Internal failure R 162 500.97 R 359 558.12 
2 Total cost of External failure R          00.00 R        410.10 
3 Total Appraisal and Prevention costs R 164 232.00 R 183 239.94 
TOTAL COST OF NON-CONFORMANCE R 326 372.97 R 543 208.16 
 
% Improvement =  (R543 208.16 – R326 372.97) x 100 
(Aspen OSD versus General Facility)         R543 208.16 
 =  39.9 % 
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The following standard costing was used for a batch size of 3 600 000 tablets. 
Table 51 – Standard cost per activity 
Activity Cost 
Standard cost of testing R      7000.00 
Standard cost per bulk batch 
Materials costs 
Conversions costs 
Total 
 
R 106 412.00 
R   58 462.00 
R 164 874.00 
Standard cost per batch (including packaging) 
Materials costs 
Conversion costs 
Total 
 
R 276 374.00 
R 162 462.00 
R 438 836.00 
   
 
5.4 Discussion 
 
Table 50 shows that the total non-conformances cost per enalapril maleate 10 mg 
tablet manufactured at Aspen OSD is forty percent (40%) lower than that of the 
General facility.  This can be seen by a substantial cost reduction of internal failures of 
product manufactured at Aspen OSD. The comparison shows that the biggest 
contributor in favour of Aspen OSD is improved yields in both the bulk tablet 
manufacture and packaging operations. Thus more raw materials are converted to 
products for sale. The increased yields account for a staggering one hundred and 
twenty one percent (121%) cost improvement for internal failure costs.   
 
Aspen OSD facility produced over sixty two batches of enalapril maleate 10 mg tablets 
over the last twelve months but only the information from five batches was used for the 
comparison.  This was done to compare equivalent number of tablets manufactured at 
both facilities.  One Aspen OSD batch size is twice that of an Aspen General Facility 
batch. Furthermore the Aspen OSD batch size is often doubled and batches of 7 200 
000 tablets are sometimes produced.  For this reason five Aspen OSD batches are 
equivalent to thirteen Aspen General Facility batches.  
 
No reworks are performed at Aspen OSD and batches that can be reworked are 
transferred to Aspen General Facility due to space constraints. Aspen OSD is not 
designed to rework products and as such no procedures exist in the quality 
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management system for reworks.  Batches for rework are transferred to Aspen 
General Facility.  Aspen General Facility is penalised with the rework cost but Aspen 
OSD is penalised with the yield loss for batches transferred to Aspen General Facility 
for rework.   
 
There were no external failure costs at the Aspen OSD facility due to no complaints 
received.  The Aspen General Facility had five complaints but the replacement value of 
product was only R410.10.  External failure cost can sometimes be difficult to assess 
as the external cost summary does not reflect the cost of losing existing customers due 
to bad products received.  Even though there were only five complaints for products 
manufactured at the Aspen General Facility, by comparison no complaints were 
received for Aspen OSD products.  This improvement cannot be quantified in monetary 
terms. 
 
Prevention and appraisal costs were not itemised due to the confidentiality of the 
information but the sum of prevention and appraisal costs were totalled in the form of 
cost per batch.   The reasons for the difference in the prevention and appraisal costs at 
the two facilities are: 
• bigger batch sizes 
• multiple batches campaigning 
• reduced product changes 
• reduced set-up times 
• specialised facility 
• structure validation 
• reduced rejects 
 
It should be noted that the figures used in the model are not accurate.  The actual 
figures were manipulated by random factorisation but for comparative purposes the 
same factorisation was applied to the information from both facilities.  
 
In summary, the cost of non-conformances for enalapril maleate 10 mg tablet is 40 % 
cheaper when manufactured in Aspen OSD as opposed to Aspen General Facility. 
This demonstrates that it is cheaper to make enalapril maleate 10 mg tablets at Aspen 
OSD than at Aspen General Facility. 
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CHAPTER 6:  DISCUSSION AND SUMMARY 
 
 
6.1 Discussion 
 
Chapter one discussed thirteen remedies that could assist organisations to ensure 
successful validation. The problems experienced during the qualification stages of the 
Aspen OSD facility, utilities and equipment was associated with six of the suggested 
remedies. At the start of the project, there was a lack of understanding of validation, 
hardly any communication between teams, a lack of experience that was linked to a 
lack of trained personnel, insufficient resources in terms of people which ultimately 
required consultants to be employed at huge costs to Aspen OSD.  The completion 
dates were unrealistic with the building completion almost four months late but the 
deadline for the first trial batch was not moved.  On the positive side, the Aspen OSD 
validation approach had standard operating procedures for validation which included 
templates for the design, installation, operational and performance qualification 
protocols, solid quality control and quality assurance support, a validation master plan 
as well as validation plans for major equipment and utilities, and the co-operation of a 
cross-functional team.   If the Aspen OSD validation approach was clearly understood 
by everyone, many problems would have been avoided and the timelines would have 
been met or completed before the deadlines. 
 
The cleaning validation problems were not so easily solved.  The lack of ownership 
combined with the fact that all operators, shift leaders, managers and senior managers 
were getting to know the new facility and the equipment was one of the reasons for the 
delayed problem solving.  Improvements in cleaning validation problem-solving have 
gathered momentum in the past twelve months, with serious involvement from 
management regarding the cleaning problems. The production department also 
restructured their staff to allow improved ownership and accountability by the 
respective operators, production pharmacists and shift leaders. This approach reduced 
the cleaning problems.   
 
The cleaning validation project is currently still ongoing and will continue with the 
introduction of each new molecule into the Aspen OSD facility until a critical mass of 
cleaning validations have been completed and a product matrix approach of molecules 
can be implemented. The product matrix approach divides products into groups of 
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products with similar solubilities, ease of cleaning, toxicity, pharmaceutical efficacy, 
and similarities of cleaning procedures amongst others. Marker products are identified 
for each group based on a worst-case selection criterion in each group, and cleaning 
validations are only performed on these marker products until a new worst-case 
marker product is selected for that group.  Aspen OSD is currently in the process of 
brain-storming the product matrix approach which will allow cleaning validation to be 
completed quickly.  
 
The results for the tablet manufacturing optimisation process were a combination of 
statistical modelling and experience. The difficulty associated with this part of 
validation is that the analytical results do not necessarily provide information that 
allows clear cut decisions.  The statistical information for the blending time optimisation 
indicated no significant difference in the position of where the sample is taken and the 
time of blending.  However, experience and logic tells us that this is not the case.  
Blending the granule for too long will cause de-mixing resulting in a batch of product 
with a host of production problems.  Hence a combination of experience, statistics and 
logic is used when decisions are made with the most decisive resting with experience.  
Decisions that can be extremely costly to the company must be approached with 
utmost care.   
 
Tablet compression optimisation gave excellent results at the different speeds for the 
parameters measured.  The results indicated that there was a ninety five percent 
chance that the true population mean values for the measured parameters were all 
within the acceptance criteria for the three validation batches.  Most of the parameters 
measured during the optimisation of tablet compression related to the physical 
properties of the tablets.  These specifications are not defined in the international 
pharmacopoeial monographs and are normally defined by the research team 
developing the product.  The use of statistical models, especially the ninety five 
percent confidence intervals to determine the best acceptance criteria for these 
parameters is recommended for future specification determinations. The overall 
evaluation of the results promoted the use of the highest speed (5000 tablets per 
minute) as the optimum tablet compression speed which favoured high production 
rates. 
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Process validation showed that the results for dry powder mix, bulk and tap densities, 
loss on drying, and blended granule were all within the acceptance criteria as well as 
consistent throughout the three batches.  The time and effort dedicated in optimising 
various parameters before embarking on process validation and major production is 
worth the wait.    
 
The process validation data for enalapril maleate 10 mg tablets gave results which 
provided two basic outcomes.  Firstly, the results for the granulation and compression 
stages of the manufacturing process matched each other relatively accurately and 
showed that the process was consistent for the three validation batches which proved 
that the optimised operating parameters for the granulation and compression stages 
were correct.  Secondly, the process for the manufacture of enalapril maleate 10 mg 
tablets, batch size 3 600 000 tablets was validated. 
 
The business model showed that the cost of non-conformance of enalapril maleate 10 
mg tablets was forty percent cheaper if the product was manufactured in Aspen OSD 
than in Aspen General Facility. This reduces the manufacturing cost for this product.  A 
factor that was not considered was the total cost of validation.  A rule of thumb is that 
validation cost is about twenty percent of the cost of the equipment.  This only includes 
design qualification, installation qualification, operational qualification and performance 
qualification.  It would be interesting to compare the total cost of validation to the 
reduction in manufacturing costs of a product to assess exactly when validation adds 
value to the company.  This was not one of the objectives of this project and thus not 
prepared.  It may be reviewed in a follow-up project.  A typical validation cost model 
would include the following items [80]: 
• Time (cost of production of analytical time) 
• People (cost of salaries of validation personnel) 
• Materials (cost of testing materials, raw materials, packaging materials) 
• Equipment (cost of analytical equipment, maintenance & calibration costs) 
• Documentation (cost of designing validation plans, protocols, approval and review). 
 
Not all aspects of validation were discussed in this project. Analytical method 
validations, raw material validations, computerised system validations, packaging 
validations, re-validation and change control were not comprehensively discussed in 
this project.  The important aspects of transforming a new pharmaceutical facility from 
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the project phase to a full scale, internationally accepted production facility were 
discussed.   
 
6.2 Summary 
 
This project has described some of the factors that influence the manufacturing 
processes of a new pharmaceutical facility. The views of local and international 
regulatory authorities, other authors and validation specialists were considered.  It has 
shown that the cost of non-conformances can be reduced by implementing a 
structured validation programme. If the necessary resources are provided and 
managed, the manufacturing costs of medicines are reduced. 
 
Validation is ultimately very necessary to fulfil regulatory requirements.  It should be 
used as a business strategy to create opportunities for organisations to maximize 
profitability and to sustain growth.  Validation costs time, money and lots of effort but it 
predominantly requires logical thinking, and the support from senior management.  A 
clear benefit of validation is that it allows the personnel to become au fait with their 
respective equipment and processes.  
 
Today’s organisations are constantly changing to improved. The rate of change in an 
organisation determines the extent of its competitive edge.  With change we have the 
introduction of new processes, and changes to existing processes. This requires 
change control, validation, and re-validation. David Begg Associates state that 
Validation is a journey and not an event [81].  It continues forever.   
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APPENDICES 
 
 
Appendix 1:  Template of a Validation Plan 
 
 
 
  
 
 
 
ASPEN ORAL SOLID DOSAGE PLANT 
 
 
Confidential Document 
 
 
VALIDATION PLAN 
 
 
Project name:  
Validation Plan number:  
Version:  
Effective Date:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page 1 of 2 
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ASPEN ORAL SOLID DOSAGE PLANT 
Validation Plan  Oral Solid Dosage Plant
 
 
 CONTENTS Page 
1  Preparation and Approval  
2  Introduction  
3  Scope  
4  Roles and Responsibilities  
5  Impact Assessment  
6  Validation approach  
7  Validation deliverables  
8  Acceptance criteria  
9  Change control  
10  Standard operating procedures  
11  Training  
12  Document Management  
13  Glossary/Abbreviations/Acronyms  
14  Planning schedule  
15  Amendment list  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Validation Plan number  Effective Date: Day Month Year Page 2 of 2 
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Appendix 2:  Template of Design Review Protocol 
 
 
 
 
 
 
 
 
ASPEN ORAL SOLID DOSAGE PLANT 
 
 
Confidential Document 
 
 
DESIGN REVIEW 
PROTOCOL 
 
Equipment/system name:  
Validation reference number  
Equipment number:  
Model:  
Serial Number:  
Department:  
Supplier Identification number:  
Protocol number:  
Addendum:  
Effective Date:  
 
 
 
 
 Page 1 of 2 
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ASPEN ORAL SOLID DOSAGE PLANT 
Design Review  Equipment/system name
 
 
 CONTENTS Page 
1  Protocol Preparation and Approval  
2  Pre-requisites  
3  Objectives  
4  System/Equipment Description  
5  Responsibilities   
6  Review requirements  
7  Record of Signatures  
8  Test/Review Data Sheets  
9  Deviations/Justification and Corrective Action  
10  Standard Operating Procedures  
11  Modification/Field Change Control  
12  Review Acceptance  
13  Design Review Summary  
14  List of Deviations  
15  List of Change Control documents  
16  Glossary  
17  References  
18  Attachments  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol number  Effective Date: Day Month Year  Page 2 of 2 
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Appendix 3:  Template of Installation Qualification Protocol 
 
 
 
 
 
 
 
 
ASPEN ORAL SOLID DOSAGE PLANT 
 
 
Confidential Document 
 
 
INSTALLATION QUALIFICATION 
PROTOCOL 
 
 
Equipment/system name:  
Validation reference number:  
Equipment number:  
Model:  
Serial Number:  
Department:  
Supplier Identification number:  
Protocol number:  
Addendum:  
Effective Date:  
 
 
 
 
 Page 1 of 2 
 
 
 
     - 121 -
 
ASPEN ORAL SOLID DOSAGE PLANT 
Installation Qualification  Equipment/system name
 
 
 CONTENTS Page 
1 Protocol Preparation and Approval  
2 Pre-requisites  
3 Objectives  
4 System/Equipment Description   
5 Responsibilities  
6 Qualification Requirements  
7 Record of Signatures  
8 Qualification Test Instrument List  
9 Overall Installation Qualification Plan  
10 Test Data Sheets  
11 Deviation /Justification and Corrective Action  
12 Standard Operating Procedures  
13 Qualification Acceptance  
14 Modification/Field Change Control   
15 Installation Qualification Summary  
16 List of Deviations  
17 List Change Control documents  
18 References  
19 Attachments  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol number  Effective Date: Day Month Year Page 2 of 2 
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Appendix 4:  Template of Operational Qualification Protocol 
 
 
 
 
 
 
 
 
ASPEN ORAL SOLID DOSAGE PLANT 
 
 
Confidential Document 
 
 
OPERATIONAL QUALIFICATION 
PROTOC0L 
 
 
Equipment/system name:  
Validation reference number:  
Equipment number:  
Model:  
Serial Number:  
Department:  
Supplier Identification number   
Protocol number:  
Addendum:  
Effective Date:  
 
 
 
 
 Page 1 of 2 
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 ASPEN ORAL SOLID DOSAGE PLANT  
Operational Qualification  Equipment/system name
 
 CONTENTS Page 
1 Protocol Preparation and Approval  
2 Pre-requisites  
3 Objectives  
4 System/Equipment Description   
5 Responsibilities  
6 Qualification Requirements  
7 Record of Signatures  
8 Qualification Test Equipment List  
9 Overall Operation Qualification Test Plan  
10 Operation Testing  
11 Test Data Sheets  
12 Deviation/Justification and Corrective Action  
13 Standard Operating Procedures  
14 Modification/Field Change Control  
15 Qualification Acceptance  
16 Operational Qualification Summary  
17 List of Deviations  
18 List of Change Control documents  
19 References  
20 Attachments  
 
 
 
 
 
 
 
 
 
 
Protocol number  Effective Date: Day Month Year Page 2 of 2 
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Appendix 5:  Template of Performance Qualification Protocol 
 
 
 
 
 
 
 
 
ASPEN ORAL SOLID DOSAGE PLANT 
 
 
Confidential Document 
 
 
PERFORMANCE QUALIFICATION 
PROTOCOL 
 
 
Equipment/system name:  
Validation reference number:  
Equipment number:  
Model:  
Serial Number:  
Department:  
Supplier Identification number  
Protocol number:  
Addendum:  
Effective Date:  
 
 
 
 
 
  Page 1 of 2 
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 ASPEN ORAL SOLID DOSAGE PLANT  
Performance Qualification  Equipment/system name
 
 CONTENTS Page 
1 Protocol Preparation and Approval  
2 Pre-requisites  
3 Objectives  
4 System/Equipment Description   
5 Responsibilities  
6 Qualification Requirements  
7 Record of Signatures  
8 Overall Performance Test Plan  
9 Performance Testing  
10 Test Data Sheets  
11 Qualification Test Equipment List  
12  Standard Operating Procedures  
13  Qualification Acceptance  
14  Deviation/Justification and Corrective Action  
15 Modification/Field Change Control  
16 Performance Qualification Summary  
17 List of Deviations  
18 List of Change Control documents  
19 References   
20 Attachments  
 
 
 
 
 
 
 
 
 
 
 
 
Protocol number  Effective Date: Day Month Year  Page 2 of 2 
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Appendix 6:  Template of Cleaning Validation Protocol 
 
 
 
 
 
 
 
 
ASPEN PHARMACARE ORAL SOLID DOSAGE PLANT 
 
 
Confidential Document 
 
 
CLEANING VALIDATION PROTOCOL 
 
 
Equipment name:  
Equipment number:  
Model:  
Serial Number:  
Department:  
Product name:  
Protocol number:  
Amendment:  
Effective Date:  
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 ASPEN PHARMACARE  
Cleaning Validation Oral Solid Dosage Plant 
 
Table of Contents Page 
1 Document Preparation and approval  
2 Objective  
3 Scope  
4 References  
5 Materials  
6 Responsibilities  
7 Background   
8 General Procedures/Definitions  
9 Change Control  
10 Limits Determination  
11 Test plan  
12 Acceptance Criteria  
13 Validation Documentation requirements  
14 Attachments 
Attachment 1 - Pre-requisites and Calibration Review 
Attachment 2 - Cleaning Procedure Documentation 
Attachment 3 - Sampling Requirements Documentation 
Attachment 4 - Test Equipment Calibrations 
Attachment 5 - Signature List 
Attachment 6 - Cleaning Validation Completion 
 
15 Amendment List  
 
 
 
 
 
 
 
Protocol number  Effective Date: Day Month Year  Page  2 of 2 
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Appendix 7:  Peak purity test chromatograms 
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Appendix 8:  Process Validation Protocol 
 
 
ASPEN PHARMACARE - PORT ELIZABETH SITE 
PROCESS VALIDATION PROTOCOL 
Product Enalapril maleate 10 mg tablets  
Document No.      Facility OSD 
 
 
 
 
 
PROCESS VALIDATION PROTOCOL 
 
 
 
Enalapril Maleate 10 mg Tablets 
 
 
 
 
 
 
Process Integrated Granulation Suite 
Batch Size 3600 000 tablets Item No  
 
 
 
 
 
 
 Prepared by 
Technical Support Pharmacist 
Approved by 
Regulatory Affairs 
Approved by 
Quality Assurance Manager 
Name    
Signature    
Date    
 
Page 1 of 2 
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ASPEN PHARMACARE - PORT ELIZABETH SITE 
PROCESS VALIDATION PROTOCOL 
Product Enalapril maleate 10 mg tablets  
Document No.      Facility OSD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Prepared by  
Technical Support Pharmacist 
Approved by 
Regulatory Affairs 
Approved by 
Quality Assurance 
Manager 
Name    
Signature    
Date    
 
Page 2 of 2 
 TABLE OF CONTENTS PAGE 
1 Purpose and scope  
2 Prerequisites  
3 Process description  
4 In process control testing equipment  
5 Support documentation  
6 Responsibilities  
7 Validation method  
8 Validation Acceptance Criteria  
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